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Paper 1 and 2 were based on the Tromsø Study, a population-based, prospective cohort 
study with repeated screenings for cardiovascular risk factors and follow-up with regard to 
disease incidence and mortality. Paper 3 was based on a local registry of consecutively 
patients with presumed ST-elevation myocardial infarction who had been given prehospital 
thrombolytic therapy, and then admitted to the University Hospital in Northern Norway in 
Tromsø. 
 
In paper 1, we showed that a substantial part of the decline in coronary heart disease 
mortality in the young and middle-aged population was due to a decreased incidence of 
myocardial infarction. The study indicates that the population burden of coronary heart 
disease may be shifting towards women and elderly patients, suggesting that preventive 
gains have not penetrated equally throughout the population. The severity and case fatality 
of the disease, however, was declining in all groups. 
 
In paper 2, we found that age- and sex-adjusted incidence of total coronary heart disease 
decreased by 3% annually over 15 years of follow-up. The decrease was found primarily in 
reductions in out-of-hospital sudden cardiac death and hospitalized ST-elevation myocardial 
infarction. Reductions in serum cholesterol accounted for approximately one-third of the 
event decline, but decreases in smoking, blood pressure, and heart rate and increased 
physical activity all contributed. Increases in body mass index and diabetes mellitus were 
associated with modest increases in disease outcomes. Overall, risk factors accounted for 




case fatality each explained approximately 50% of the decline in coronary heart disease 
mortality. This was partly explained by less severe disease in those afflicted, but also by a 
major improvement in treatment. 
 
In paper 3, we showed that ambulance clinicians with the support of hospital cardiologists 
could safely and effectively perform prehospital thrombolytic therapy. The implementation 
of this system was associated with significant reduction in time delays of reperfusion 
therapy, and reduction in post-infarct systolic heart failure, and high survival rates among 
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List of definitions 
Acute coronary syndrome - an episode of myocardial ischemia that generally lasts longer 
than a transient anginal episode that ultimately may lead to myocardial infarction (1). 
Atherosclerosis - a thickening and loss of elasticity of the walls of arteries that occurs with 
formation of atherosclerotic plaques within the arterial intima (1). 
Biomarkers - measurable and quantifiable biological parameters (e.g., specific enzyme 
concentration, specific hormone concentration, specific gene phenotype distribution in a 
population, presence of biological substances) which serve as indices for health- and 
physiology-related assessments, such as disease risk, psychiatric disorders, environmental 
exposure and its effects, disease diagnosis; metabolic processes; substance abuse; 
pregnancy; cell line development; epidemiologic studies; etc. (1). 
Case-control study - a type of observational analytic study. Enrollment into the study is 
based on presence (``case'') or absence (``control'') of disease. Characteristics such as 
previous exposure are then compared between cases and controls (2). 
Case fatality rate – the proportion of persons with a particular condition (cases) who die 
from that condition. The denominator is the number of incident cases; the numerator is the 
number of cause-specific deaths among those cases (2). 
Case-series - a type of observational descriptive study that follows a group of consecutive 
patients who have a similar diagnosis or who are undergoing the same procedure over a 




Cohort study - a type of observational analytic study. Enrollment into the study is based on 
exposure characteristics or membership in a group. Disease, death, or other health-related 
outcomes are then ascertained and compared (2).  
Coronary angiography - radiography of the vascular system of the heart muscle after 
injection of a contrast medium (1). 
Coronary heart disease - an imbalance between myocardial functional requirements and the 
capacity of the coronary vessels to supply sufficient blood flow. It is a form of myocardial 
ischemia (insufficient blood supply to the heart muscle) caused by a decreased capacity of 
the coronary vessels (1). 
Echocardiography - ultrasonic recording of the size, motion, and composition of the heart 
and surrounding tissues (1). 
Electrocardiography - recording of the moment-to-moment electromotive forces of the 
heart as projected onto various sites on the body's surface, delineated as a scalar function of 
time. The recording is monitored by a tracing on slow moving chart paper or by observing it 
on a cardioscope, which is a cathode ray tube display (1). 
Epidemiologic studies - studies designed to examine associations, commonly, hypothesized 
causal relations. They are usually concerned with identifying or measuring the effects of risk 
factors or exposures. The common types of analytic study are case-control studies; cohort 
studies; and cross-sectional studies (1). 
First medical contact – the time point when the patient is either initially assessed by a 




obtain and interpret the electrocardiogram, and deliver initial interventions (e.g. 
defibrillation). First medical contact can be either in the prehospital setting or upon patient 
arrival at the hospital (e.g. emergency department) (4).  
Incidence rate - a measure of the frequency with which an event, such as a new case of 
illness, occurs in a population over a period of time. The denominator is the population at 
risk; the numerator is the number of new cases occurring during a given time period (2). 
Mortality rate - a measure of the frequency of occurrence of death in a defined population 
during a specified interval of time (2). 
Myocardial infarction - necrosis of the myocardium caused by an obstruction of the blood 
supply to the heart (coronary circulation) (1). 
Myocardial ischemia - a disorder of cardiac function caused by insufficient blood flow to the 
muscle tissue of the heart. The decreased blood flow may be due to narrowing of the 
coronary arteries (coronary heart disease), to obstruction by a thrombus (coronary 
thrombosis), or less commonly, to diffuse narrowing of arterioles and other small vessels 
within the heart. Severe interruption of the blood supply to the myocardial tissue may result 
in necrosis of cardiac muscle (myocardial infarction) (1). 
Myocardium - the muscle tissue of the heart. It is composed of striated, involuntary muscle 
cells (myocytes) connected to form the contractile pump to generate blood flow (1). 
Necrosis - the pathological process occurring in cells that are dying from irreparable injuries. 
It is caused by the progressive, uncontrolled action of degradative enzymes, leading to 
mitochondrial swelling, nuclear flocculation, and cell lysis. It is distinct it from apoptosis, 




Non-ST elevated myocardial infarction - a myocardial infarction that does not produce 
elevations in the ST segments of the electrocardiogram. ST segment elevation of the ECG is 
often used in determining the treatment protocol (1). 
Prevalence - the total number of cases of a given disease in a specified population at a 
designated time. It is differentiated from incidence, which refers to the number of new cases 
in the population at a given time (1). 
Risk factor - an aspect of personal behavior or lifestyle, environmental exposure, inborn or 
inherited characteristic, which, on the basis of epidemiological evidence, is known to be 
associated with a health-related condition considered important to prevent (1). 
ST elevation myocardial infarction - a clinical syndrome defined by myocardial ischemia 
symptoms; persistent elevation in the ST segments of the electrocardiogram; and release of 
biomarkers of myocardial necrosis (e.g., elevated troponin levels). ST segment elevation in 
the ECG is often used in determining the treatment protocol (1). 










1. Introduction of acute myocardial infarction 
1.1 Causes, manifestations, and treatments of acute coronary syndrome 
 
Cardiovascular disease is a group of diseases that include both the heart and blood vessels, 
thereby including coronary heart disease (CHD). The cause of CHD is in most cases stenosis 
or occlusion of one or more coronary artery branches due to atherosclerosis. The main 
manifestations of CHD are stable angina pectoris, heart failure, and acute coronary 
syndrome (ACS), i.e. unstable angina pectoris (UAP), myocardial infarction (MI), and sudden 
cardiac death (SCD). Central to the pathogenesis of ACS is plaque rupture or erosion with 
overlying thrombosis and increased tendency to spasm (5). MI occurs when there is cell 
death (necrosis) due to significant and sustained ischaemia, as measured by a blood test for 
biomarkers (the cardiac protein troponin T (cTnT) or I (cTnI), and the cardiac enzymes CK and 
CK-MB).  
 
Based on the electrocardiogram (ECG), two groups of ACS patients can be separated: (1) 
Patients with acute chest pain and persistent (>20 min) ST-segment elevation. This condition 
often reflects an acute thrombotic total coronary occlusion, and most patients will develop 
an ST-elevation myocardial infarction (STEMI). (2) Patients with acute chest pain but no 
persistent ST-segment elevation. The pathological correlate at the myocardial level is 
cardiomyocyte necrosis [non-ST-elevation myocardial infarction (NSTEMI)] or, less 
frequently, myocardial ischaemia without cell death (UAP). UAP and NSTEMI normally result 





The ACS model places UAP, NSTEMI, and STEMI at increasingly severe points along a disease 
continuum (6). Based on the ECG, STEMI and NSTEMI ultimately develop with little crossover 
into Q-wave and non-Q-wave MI, respectively. The division of MI into Q-wave or non-Q-
wave is useful because the presence of Q-waves predicts a lower heart function and a larger 
MI (7).     
 
The cornerstone of treatment in patients with STEMI is immediate reperfusion, either 
mechanical by percutaneous coronary intervention (PCI), or pharmacological by 
thrombolytic therapy (4, 8). In comparison, a routine invasive strategy with coronary 
angiography and myocardial revascularization is usually recommended within 2-3 days in 
patients with NSTEMI (9). Coronary artery bypass grafting (CABG) is also a method for 
coronary revascularization in a subset of the patients (10). Furthermore, the early drug 
treatment in patients with MI aims to reduce myocardial ischemia (nitroglycerin, β-blockers) 
and diminish the thrombotic process [aspirin, P2Y12 inhibitor (clopidogrel, prasugrel, or 
ticagrelor), and either unfractionated heparin, enoxaparin, or fondaparinux]. Randomized 
trials provide robust evidence for the impact of pharmacological and interventional 
treatments in patients with ACS (4, 8, 9). 
 
Many previous studies have found that a large proportion of CHD deaths occur outside of 
hospitals as SCD (11-15). Classification and disease surveillance of out-of-hospital CHD death 
is usually deficient because of its sudden onset, lack of witnesses, and low autopsy rates 
(16). Prospective epidemiological studies can provide more pre event information. Although 
the immediate mechanism of death is ventricular fibrillation or asystole, CHD is by far the 




Approximately 20% of CHD patients have sudden cardiac death as the first clinical 
manifestation (14, 21).  
 
1.2 Cardiovascular risk factors 
 
The lifetime risk for CHD varies depending on the profile of several well‐known risk factors. 
These include age, gender, lipid profile, blood pressure, smoking status, and diabetes. The 
identification of risk factors and their control through preventive measures has contributed 
to a reduction in CHD and related mortality in both men and women (22, 23). When all 
modifiable risk factors are optimal, the lifetime risk of CHD for a 45 year‐old is estimated to 
be <5%, whereas with ≥2 major risk factors, it is 50% for men and 31% for women (24). 
Specific to MI, the INTERHEART Study, a global case‐control study across 52 countries (and 
including 15,152 incident cases of hospitalized MI and 14,820 controls), identified 9 risk 
factors (smoking, lipids, hypertension, diabetes, obesity, diet, physical activity, alcohol 
consumption, and psychosocial factors) that accounted for over 90% of the population 
attributable risk of MI (25). These risk factors were the same in almost every geographic 
region and racial/ethnic group worldwide, and were similar for men and women. 
Dyslipidemia and smoking were rated as the most important modifiable risk factors (25). 
However, the INTERHEART Study has several potential limitations. A case-control design is 
open to confounding and bias, and the study was limited to survivors. There is a lack of 
prospective observational studies, which have looked directly at how changes in risk factors 





Prevalence of obesity in the United States has increased dramatically in recent decades (as in 
other Western countries), but, except for diabetes, other risk factors have declined 
considerably in all body mass index (BMI) groups (26). Using 2008 American Diabetes 
Association criteria, the prevalence of diabetes was 15.3% during 1988–1994 and 17.5% 
during 2005–2006 (27). Smoking habits have changed in the United States and Europe in 
recent decades, with a fall for men and a smaller decline for women (Figure 1) (28, 29). 
 
Figure 1. Percentage of daily smokers according to gender in persons aged 16–74 in Norway 




CHD is more common in men than in women. In the INTERHEART study women experienced 
their first MI on average 9 years later than men. The difference in age of first MI was mainly 
explained by the higher risk factor levels at younger ages in men compared to women (30). 
In both sexes, CHD risk increases with age, and the sex difference persists throughout life, 




(31). In a prospective follow-up study from Finland differences in major cardiovascular risk 
factors explained a substantial part of the sex difference in CHD risk (32). However, in a 
large, prospective population study in Norway the higher risk of MI in men compared with 
women could not be explained by differences in established risk factors (31). 
 
1.3 Time trends and burden of coronary heart disease mortality 
 
CHD is a major cause of death and disability in developed countries. (33-35). Although age-
adjusted CHD mortality rates have declined over the last decades in western countries, CHD 
remains responsible for about one-third or more of all deaths in individuals over age 35 (34, 
35). Mortality data from the Global Burden of Disease Study 2013 showed that the aging and 
growth of the population have resulted in an increase in global number of cardiovascular 
deaths, despite a decrease in age-specific death rates in most regions (36, 37). Only in 
Central Europe and Western Europe did the annual number of deaths from cardiovascular 
disease actually decline. Globally, CHD has become the leading contributor to the burden of 
disease as assessed based on disability-adjusted life-years (38).  
 
Acute MI is the major contributor to CHD incidence and mortality. In epidemiological studies, 
the incidence of MI in a population can be used as a proxy for estimating the CHD burden. 
Furthermore, MI incidence forms the most relevant indicator for the effect of primary 
prevention in reducing CHD. If standardized data can be collected on SCD and incident and 




The mortality from MI in Norway has been changing rapidly in both genders since 1970 but 
with a more marked fall for men (Figure 2). 
 
Figure 2. Mortality from myocardial infarction in men and women over a 37-year period. 




1.4 Changes in myocardial infarction definition  
 
Evaluating temporal trends in the incidence and outcome of MI is challenging since there 
have been changes over time in the criteria utilized for the diagnostic confirmation of MI. 
The definition of acute MI was introduced by the World Health Organization (WHO) in 1959 




and the Framingham Study provided further specifications (41-43). The WHO criteria were 
revised in 1979 (44). The diagnosis of MI was based on the presence of at least two of three 
criteria: cardiac symptoms, ECG changes, and increase in enzymes indicating myocardial 
injury. The definitions of the three criteria have varied among researchers, resulting in a lack 
of comparability among and within studies. This was the background for the WHO 
multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) 
project, which was set up to measure the trends in cardiovascular mortality and incident 
CHD, classifying the events into five categories (definite, possible, ischemic cardiac arrest, no 
MI or coronary death, and unclassifiable), related to risk factors (45, 46).  
 
In 2000, the European Society of Cardiology (ESC) and the American College of Cardiology 
(ACC) recommended changing the diagnostic criteria for acute MI to include raised cTn 
concentrations in addition to ischemic symptoms or ECG changes of ischemia (47). This 
definition includes only the definite category of MI, which may lead to underestimation of 
the incidence of MI in epidemiological studies. The ESC/ACC was criticized for changing the 
definition of MI, first because of problems with comparisons with previous definitions and 
populations, secondly because of failure of the new definition to cover SCD, and thirdly 
because the new definition did not include nonfatal cases with missing cTn results (48-51). In 
2003 epidemiological researchers published an AHA scientific statement to address the 
specific needs regarding the definition of MI in population surveillance (16). Later, the ESC, 
ACC, AHA and World Heart Federation (WHF) published the Universal 2007 definition which 
addressed several of the weaknesses of the 2000 definition, and included five new 
categories of MI (52). In addition, some changes were made in the WHO 2009 revision (39) 





1.5 The problems with new sensitive biomarkers 
 
The most complicating factors in many studies of MI trends during the past decades, are the 
increasing use of cardiac biomarkers and the changing cutoff levels for the laboratory tests 
used for the diagnosis of MI (52, 54, 55). In the Framingham Heart Study trends in MI 
incidence were highly dependent on the definition used. ECG-diagnosed MI incidence 
decreased by 50% between 1960 and 1999, but biomarker-diagnosed MI incidence increased 
2-fold (55). Compared with CK and CK-MB, cTns are more sensitive and specific markers of 
myocyte necrosis. The higher sensitivity allows detection of small amounts of myocardial 
necrosis that would have gone undetected by CK and its MB fraction. Thus, this biomarker 
change was predicted to increase the number of smaller MIs, predominantly NSTEMIs, and 
this increase could obscure declining trends in the incidence of coronary events (56, 57). 
Given current sensitive biomarkers, the proportion of ACS without necrosis (UAP) has 
declined to a small fraction (≈7%) of ACS presentations. Thus, the hospitalized ACS spectrum 
is now dominated by MI, composed of STEMI (≈1/3 of MIs) and NSTEMI (≈2/3 of MIs), with 
their differing prognostic and therapeutic implications (58).  
 
There have been a number of studies evaluating the impact of the ESC/ACC 2000 
redefinition of MI on the frequency of diagnosis of MI. The increase in the number of MIs 
due to the increased sensitivity of cTn ranges from 4 % to 195 % (56, 57). In a prospective 
Minnesota US community study of patients hospitalized with incident MI from 1987 to 2006, 
25% of incident MIs met only cTn-based criteria after cTn was introduced. When cases 




defined by CK/CK-MB, the incidence of MI declined by 20%. The incidence of NSTEMI 
increased markedly by relying on cTn, whereas that of STEMI declined regardless of cTn. The 
severity of infarctions declined regardless of cTn, and the 30-day case fatality improved 
markedly over time (59). In the Finnish Acute MI (FINAMI) study, the effect of cTns on the 
incidence of first coronary events tended to be stronger in women and older individuals than 
in men and younger individuals (60). However, the case fatality trends, with a decline in both 
sexes in patients aged 35–74 years, were not affected by adjustment for cTns. The 
redefinition of MI has indeed been shown to identify some patients with ACS who are older 
and more often female and who have greater comorbidities and worse 6-month and 1-year 
outcomes who were missed by the old 1979 WHO criteria (61-63).  
 
The clinical acceptance of the new definition, however, was initially incomplete. In one study 
less than half of the cases identified with the new criteria were documented as MI in the 
medical record (57). A survey in Scotland in 2002 (64) showed that only one-third of 
cardiologists made a diagnosis of MI when patients presented with chest pain and elevated 
cTn levels in the absence of ECG changes or elevated CK or CKMB levels. One study has 
shown that the new diagnostic criteria for MI were not applied methodically in the hospital 
studied, and that males with raised cTn T values were more likely to be discharged as having 
had an MI than females (65). 
 
1.6 Contributors to the fall in CHD mortality 
 
Mortality rates are subject to a number of influences such as changes in risk factors, 




may be driven by reductions in the incidence of coronary events and/or increased survival of 
those affected. Changes in incidence may reflect the effects of primary prevention with 
improvements in the levels of population risk factors (46, 66). Changes in case fatality are 
assumed to be caused by improvements in initial hospital-based treatment and subsequent 
postdischarge management, while the recurrence rate depends on the success of secondary 
prevention efforts and treatment of chronic CHD. However, the effects of treatment and 
prevention may overlap. It is possible that interventions to prevent the initial MI, also can 
change the case fatality rate after an MI. The severity of incident MI may therefore be 
influenced by both primary prevention efforts, which might result in less severe events from 
the earliest stages, and acute care, which might preserve cardiac tissue and function (67). 
Consequently, improvements in population risk factors would not only prevent an initial MI 
but also shift the distribution of MIs toward less severe forms.  
 
Epidemiological studies provide an opportunity to examine whether the severity of acute MI 
differs according to time, place and persons. Indicators of severity can be Killip class 
(quantifies severity of heart failure in ACS), biomarkers (peak CK, CK-MB or cTn), ECG 
findings (Q-wave, ST-segment elevation), and case fatality rate. However, evaluating the 
severity of MI may be difficult (33, 68). The time between symptom onset and presentation 
to medical care can affect each indicator of severity. Biomarkers and Q-wave can be 
influenced by treatment, particularly reperfusion, while ST-segment elevation reflect the 
characteristics of the MI during the first hours and are therefore not affected by treatment. 
However, the interpretation of the changes in STEMI requires knowledge in the trends in 
out-of-hospital CHD deaths, since a decline in hospitalized STEMI rates could reflect an 




through biomarker measurement will be affected by the timing and frequency of the 
biomarker measurements such that the recorded values may not accurately reflect the true 
peak. However, measurement of cTnT at a single point of time on any of the first 4 days or 
using the peak value correlates well with infarct mass determined by contrast-enhanced 
magnetic resonance imaging (69). cTnT serum concentrations show a biphasic curve with 
one peak on the first day resulting from a release of the cytosolic cTnT pool and a second 
“plateau” phase 3–4 days after the beginning of chest pain resulting from intramyocardial 
protein degradation. Compared with cytosolic markers (CK, CK-MB), the second peak of cTnT 
seems to be almost unaffected by early coronary reperfusion (70). 
 
1.7 The IMPACT model  
 
Researchers have used mathematical models which include data on major risk factor levels 
in the population and data on the use of medical treatments and interventions to try to 
explain the observed decline in CHD mortality (71). The IMPACT CHD mortality model is a 
cell-based model originally developed by Capewell and colleagues in 1996 (72). Using a MS 
EXCEL spreadsheet, this aggregate model combines data from many sources on patient 
numbers, treatment uptake, treatment effectiveness, and risk factor trends to model CHD 
mortality. The model is used to estimate the proportion of a mortality decline (or increase) 
over a certain time span that might be attributed to specific treatments or to risk factor 
changes. The validity of the model has been checked by comparing the estimated fall in CHD 
deaths with the observed fall in specific age and sex categories. Based on this model it has 
been suggested that risk factor improvements explain more of the mortality decline than 




in Sweden between 1986 and 2002 was attributable to reductions in major risk factors, 
mainly a large decrease in total serum cholesterol (81). Adverse trends were seen for 
diabetes and overweight, but not so much as in US (78). Medical and surgical treatments 
explained nearly 40 % of the mortality reduction. The largest reduction came from the use of 
secondary-prevention medications after MI, followed by initial treatment for MI and UAP 
and treatments for heart failure.  
 
 These studies based their estimates on ecological data and mathematical modeling of 
aggregate data. Studies based on aggregate data are often referred to as an ecological 
design. The association found with aggregate data may not apply to individuals (ecological 
fallacy). We found only two studies that have looked directly at how changes in risk factors 
in a cohort correspond to changes in MI incidence using individual data (82, 83), and these 
two studies were limited to population subgroups and did not study out-of-hospital CHD or 
subtypes of MI. However, there are very few populations in the world where it is possible to 
do such studies. The Tromsø Study is unique here.   
 
1.8 Cardiovascular registers and population-based epidemiological studies 
 
Randomized trials provide robust evidence for the effects of pharmacological and 
interventional treatments in patients with MI, and such studies may influence practice 
guidelines depending on their quality and generalizability. To improve quality of care and 
ensure adherence to guidelines, registries in various countries have been developed (84-87). 
In Norway, nationwide studies on MI incidence have not been possible due to lack of 




has been operating since December 2012 and is a national person-identifiable health register 
that does not require the consent of the registered patient. The register consists of a basic 
register containing data from the Norwegian Patient Register and the Cause of Death 
Register, and currently has eight associated national medical quality records. NCVDR 
therefore provides information on all patients admitted for acute MI in the entire country, 
their individual baseline characteristics, the use of evidence-based treatments, and the 
short- and long-term outcome.  
 
Cardiovascular disease registries have provided important contributions to our 
understanding of outcomes in MI. However, the inability to quantify or characterize the 
underlying populations from which their patients are drawn limits their usefulness in 
studying disease incidence and the potential effectiveness of primary prevention efforts 
(54). Population-based epidemiologic data, such as that from the Tromsø Study, provide the 
best evaluation of the risk factors that contribute to the development of CHD and to the way 
CHD evolves, progresses, and terminates. Additionally, these data are less restricted by the 
unavoidable selection bias of clinical trials data. Therefore, population-based studies on 
trends in MI have been the principal source of knowledge in the understanding of MI 
epidemiology. However, existing literature assessing recent temporal trends in the incidence 
of MI is relatively sparse, and studies often lack sufficient power and diversity (54). 
 
1.9 Recent trends in myocardial infarction epidemiology and unresolved issues 
 
Several studies have examined temporal trends in the incidence of MI. Interpreting and 




temporal changes in the criteria used to diagnosis MI, and differences in study methodology. 
However, the overall body of literature suggests that the incidence of MI has declined 
significantly over the past decades (88). Trends in the incidence rate of MI in the United 
States may have changed from relatively stable rates in the 1980s and 1990s (89, 90) to 
significant declines in the new millennium (6, 55, 59, 91-93). Since 1987, the adjusted 
incidence rate of hospitalization for acute MI or fatal CHD in the United States has declined 
by 4 to 5% per year (94).  In Seattle, the age- and sex-adjusted incidence rates of out-of-
hospital cardiac arrest with ventricular fibrillation from 1980 to 2000 declined by 56%, and 
the incidence of all treated arrests declined by 34% (95). Numerous publications have 
documented improvements in the in-hospital or short-term case-fatality rate (6, 55, 59, 89, 
92, 93, 96). One-year postdischarge death rates decreased between 1997 and 2005 for 
patients with STEMI and NSTEMI (6). In the Framingham Study, 1- and 5-year mortality 
among adults who had an MI decreased by 65% and 64%, respectively, during the period 
from 1960 to 1999 (55). 
 
Recent publications from the Nordic (97-101) and other European countries (83, 102, 103) 
have also reported decreases in MI incidence and case fatality rates. Both hospitalized case-
fatality and out-of-hospital mortality have been reported to decrease over time (11, 102, 
104-107). Autopsy data have reported a reduced prevalence of anatomic CHD over time in 
both the general population and military personnel (108, 109). 
 
Relatively few population-based studies have examined recent temporal trends in the 




conditions into the single category of MI may be misleading, because these MI subtypes to 
some extent have different treatments, and impose different burdens on patients, 
physicians, and health care systems. Furthermore, we are not aware of prospective studies 
of predictors of the three MI subtypes, i.e. studies that compared premorbid characteristics 
/risk factors. Because the clinical history of patients with these individual conditions may 
differ, cross-sectional data collected from medical records at the time of the event may not 
reflect premorbid characteristics. We know that there is a consistent pattern for STEMI to be 
relatively more common in younger than in older people, and more common in men than in 
women (6, 110-113). Compared to NSTEMI patients, those with STEMI are less likely to have 
a prior history of several comorbidities (6, 111). In addition, STEMI patients are more likely 
to receive effective cardiac medications and PCI (6).  
 
Despite large falls in MI rates differences continue to exist across population subgroups: the 
decline in incidence may not have happened equally in men and women, the young and the 
elderly and across socioeconomic groups. Most studies report overall age-standardized 
rates, and data on age-specific trends are sparse. In young adults flattening of the decline 
and even increases in AMI incidence have been observed (96, 97, 114). Furthermore, falls in 
MI incidence have been reported to be greater in men than women (114-118). Emerging 
trends in coronary risk factors support these observations (29, 119,120). In a 2009 report 
that used National Health and Nutrition Examination Survey (NHANES) data, MI prevalence 
in the US was compared by sex in middle-aged individuals (35–54 years) during the 1988–
1994 and 1999–2004 time periods (119). The study found a higher prevalence of MI in men 
compared with women in the two periods, but prevalence tended to decline in men over 




epidemiology of MI are needed to help assess the effectiveness of primary prevention and 
treatment and identify areas for potential improvement (54). 
 
1.10 Treatments of ST-segment elevation myocardial infarction 
 
Although recent population-based studies indicate a reduction in incidence, STEMI is still a 
major health issue worldwide (6, 59, 92). In a recent study describing the current situation in 
30 European countries, the annual incidence for hospital admissions for STEMI varied 
between 44 and 142 cases per 100 000 inhabitants (121). Primary PCI and thrombolysis have 
been proven to preserve left ventricular function and lower infarct size and mortality (122, 
123). Randomized clinical trials have shown that, if delay to treatment is similar, primary PCI 
is superior to thrombolysis in reducing mortality, reinfarction, or stroke (123). Therefore, 
primary PCI is preferred over thrombolytic therapy in acute STEMI, but only if PCI is 
performed in a timely fashion, i.e. within 90 to 120 min from first medical contact (FMC) (4, 
8).  Both randomized studies and registries have indicated that long delays to primary PCI are 
associated with worse clinical outcomes.  
 
Generally, thrombolysis is more widely available and can be started earlier than primary PCI. 
In settings where primary PCI cannot be performed in a timely fashion, thrombolysis should 
be considered, particularly if it can be given in a pre-hospital setting (e.g. in the ambulance) 
(124-128) and within the first 120 min of symptom onset (129-132). The pharmaco-invasive 
strategy combining prehospital thrombolytic therapy (PHT) and rapid transfer to planned PCI 
within 3-24 hours in stable patients, and rescue PCI for failed thrombolysis, is an efficient 




PHT strategy with primary PCI in patients who present early show no difference in 30-day 
mortality or re-infarction (124, 128).  
 
An early study showed that the benefits of aspirin and thrombolytics (i.e. streptokinase) 
were additive (137). Clopidogrel added to aspirin will further reduce the risk of 
cardiovascular events and overall mortality in patients treated with thrombolysis (138). 
Parenteral anticoagulation should preferably be given until revascularization (if performed), 
and the net clinical benefit favored enoxaparin over unfractionated heparin in the ASSENT 3 
trial (139). Weight-adjusted i.v. tenecteplase, aspirin, and clopidogrel given orally, and 
enoxaparin i.v. followed by s.c. administration until the time of PCI (revascularization), 
comprise the antithrombotic cocktail most extensively studied as part of a pharmacoinvasive 
strategy (4). 
 
If trained medical or paramedical staff are able to analyze the ECG onsite or to transmit the 
ECG to the hospital for interpretation, it is recommended to initiate thrombolytic therapy in 
the pre-hospital setting. The aim is to start thrombolytic therapy within 30 min from FMC (8) 
[(within 20 min in the latest guidelines from 2017 (4)]. However, only limited information is 
available on the speed of implementation of this new treatment strategy and its association 
with morbidity and mortality in real-life health care (140). 
 
1.11 Predictors of outcome with ST-segment elevation myocardial infarction 
 
Thrombolytic therapy is associated with a small but significant excess of cerebral 




population studied (128). Left ventricular (LV) systolic dysfunction is a complication following 
MI and can be transient (i.e. myocardial stunning) or persistent due to cell loss (MI), 
depending on the duration of ischemia and completeness of reperfusion. LV systolic 
dysfunction is a powerful independent predictor of mortality (142, 143). LV dysfunction may 
be clinically silent or cause clinical heart failure, and the diagnosis is made by clinical and 
imaging techniques, most frequently echocardiography, with estimating of the LV ejection 
fraction (LVEF). LVEF is the ratio of blood ejected during systole (stroke volume) to blood in 
the ventricle at the end of diastole (end-diastolic volume), i.e. a percent measurement of 
how much blood the left ventricle pumps out with each contraction. A normal heart's LVEF 
may be between 50% and 70%. Trials in both the pre- and the post-thrombolytic era have 
shown that an LVEF of 40% is the break point separating patients at relatively low, versus 
higher, mortality risk (144-146). Heart failure is the most frequent complication and one of 
the most important prognostic factors in patients with STEMI (147, 148). Cardiogenic shock 
is defined as persistent hypotension (systolic blood pressure <90mmHg) despite adequate 
filling status with signs of hypoperfusion. It complicates 6–10% of all cases of STEMI and 
remains a leading cause of death, with in-hospital mortality rates ≥50 % (149).  
 
The mortality in STEMI patients is influenced by many factors, among them advanced age, 
heart failure, time delay to treatment, presence of emergency medical system (EMS)-based 
STEMI networks, treatment strategy, history of MI, diabetes mellitus, renal failure, number 
of diseased coronary arteries, and LVEF (4). Several recent studies have observed a fall in 
acute and long-term mortality following STEMI in parallel with greater use of reperfusion 
therapy, primary PCI, modern antithrombotic therapy, and secondary prevention (86, 150-




approximately 10% (153, 154). Overall, NSTEMI patients appear to have lower short-term 
mortality compared with STEMI individuals, while at 1- or 2-years follow-up the mortality 
rates become comparable. This is likely due to differences in baseline characteristics, 




















2. Aims of the thesis 
 
The main aim of the thesis was to describe recent trends in incidence, risk factors, severity, 
treatment and outcome of MI in a general Norwegian population during the time period 
1974 -2012. 
More specifically, our main focus has been: 
1. To examine gender- and age-specific trends in incidence, case fatality and the severity of 
first MI over a 30-year follow-up. 
2. To study trends in the rates of out-of-hospital SCDs, and the incidence, treatment, and 
outcome of hospitalized STEMI and NSTEMI, and the impact of changes in coronary risk 
factor levels on event rates. 
3. To study clinical results following implementation of a decentralized PHT-system 
combined with improved availability of 7/24 invasive diagnosis and treatment-service in 











3.1 Study population and follow-up used in paper 1-2 
 
The rapid increase of CHD mortality in Northern Norway during 1951–1970, and the higher 
CHD mortality figures in this region than in the rest of the country, led the University of 
Tromsø, established in 1972, to start a study to identify the major operating cardiovascular 
risk factors in this population. The Tromsø Study is a single-centre, population-based, 
prospective health study conducted in the municipality of Tromsø (156, 157). Tromsø is the 
regional centre and the largest city in Northern Norway. Tromsø had about 40,000 
inhabitants in 1974, whereas the population in 2018 is about 75,000. The University Hospital 
of Northern Norway in Tromsø (UNN Tromsø) is the only hospital in the area. The Tromsø 
Study consists of seven repeated health surveys (Tromsø 1: 1974, Tromsø 2: 1979-80, 
Tromsø 3: 1986-87, Tromsø 4: 1994-95, Tromsø 5: 2001-02, Tromsø 6: 2007-08 and Tromsø 
7: 2015-16). Both total birth cohorts and random samples of Tromsø inhabitants were 
invited by written mail-sent invitations. The overall participation rate ranged from 65-85 %. 
Women were included in the 1979 survey and onwards. An overview over the Tromsø Study 
sample is given in table 1.   
 
No national registry of cardiovascular diseases existed in Norway until 2012. Therefore, the 
Tromsø study had to establish its own disease registry covering incident MI, and later on also 





Table 1. Overview of the Tromsø study 1974–2016. 
 
Year  Survey  Participants  Age (years) Attendancea 
1974 Tromsø 1 6595 men 20-49 83 % 
1979-80 Tromsø 2 16,621 men and women                       20-54 85 % 
1986-87 Tromsø 3 21,826 men and women 12-67 81 % 
1994-95 Tromsø 4 27,158 men and women 25-97 77 % 
2001-02 Tromsø 5 8130 men and women 30-89 79 % 
2007-08 Tromsø 6 12,984 men and women 30-87 66 % 
2015-16 Tromsø 7 21,083 men and women 40-99 65 % 
 
a Of eligible population (adjusted for deaths and emigration from Tromsø). 
 
Paper 1 is a follow-up study of gender- and age-specific trends in incidence, case fatality and 
the severity of first MI among all participants from the first five surveys (Tromsø 1-5: 1974-
2002). They were followed from the date of first attendance at the population health 
screening until date of first-ever fatal or non-fatal MI, emigration from Tromsø, death from 
other causes or 31th December 2004, whichever came first.  All analyses were stratified by 
sex and age (35–49 years, 50–64 years, 65–79 years and 80 years and older). To ensure valid 
trends with stable average age within each age group, we had to take into account that the 
oldest birth cohorts were recruited later than the younger ones (Table 1). Therefore, for 




and older could be performed for the time periods 1974–2004, 1988–2004 and 1995–2004, 
respectively. For women, age-specific trend analyses for the age groups 35–49 years, 50–64 
years and 65 years and older could be carried out for the time periods 1979–2004, 1993–
2004 and 1995–2004, respectively. A total of 31,323 participants were included in the 
analysis, 15,566 men and 15,757 women. 
 
Paper 2 includes participants from the surveys undertaken in 1994-95 (Tromsø 4), 2001-02 
(Tromsø 5), and 2007-08 (Tromsø 6), a total of 29,582 individuals ≥25 years who participated 
in 1, 2, or all 3 surveys. Follow-up extended from the date of first attendance in the 
population health screening to the date of incident event, date of emigration, death, or end 
of follow-up (31 December 2010), whichever came first. We studied the rates of out-of-
hospital SCDs, the incidence, treatment, and outcome of hospitalized STEMI and NSTEMI, 
and the impact of changes in coronary risk factor levels on incidence trends. Participants 
who were still free of MI and attended the later surveys in 2001 to 2002 or in 2007 to 2008 
had their CHD risk factor values updated at the date of their examination. 
 
3.2 Study population, inclusion and exclusion criteria, and follow-up used in paper 3 
 
The study population was recruited from UNN Tromsø’s local catchment area (23100 km
2
) 
with about 125 000 inhabitants. The annual number of STEMI in this population is about 80-
100. We included patients with presumed STEMI where primary PCI could not be performed 
within 90-120 min of FMC, and with PHT-decisions based on 12-leads ECG transmitted to 




with or without radiation, pain duration between 20 min and 6 hours, and ECG indicative of 
an acute STEMI: ≥2 mV ST-segment elevation in at least 2 contiguous leads or presumed new 
left bundle branch block. Exclusion criteria was age >80 years or standard contraindications 
to thrombolysis (table 2).  
Table 2. Contra-indications to fibrinolytic therapy (4) 
Absolute 
Previous intracranial hemorrhage or stroke of unknown origin at anytime 
Ischemic stroke in the preceding 6 months  
Central nervous system damage or neoplasms or arteriovenous malformation 
Recent major trauma/surgery/head injury (within the preceding month) 
Gastrointestinal bleeding within the past month 
Known bleeding disorder (excluding menses) 
Aortic dissection 
Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture) 
Relative 
Transient ischaemic attack in the preceding 6 months  
Oral anticoagulant therapy 
Pregnancy or within 1 week postpartum 
Refractory hypertension (SBP>180 mmHg and/or DBP>110 mmHg) 
Advanced liver disease 
Infective endocarditis 
Active peptic ulcer 
Prolonged or traumatic resuscitation 




We examined 385 consecutively patients with presumed STEMI who had been given PHT, 
and then admitted directly to UNN Tromsø between March 2000 and December 2011. They 
were followed one year after index event with regard to mortality.  
 
3.3 Myocardial infarction case identification and definition used in paper 1 and 2 
 
Adjudication of hospitalized and out-of hospital events was performed by an end-point 
committee using information in medical records and medical notes, autopsy records, and 
death certificates. The national unique 11-digit identification number allowed linkage to 
national and local diagnosis registries. Cases of hospitalized MI were identified by searching 
the discharge diagnosis registry at UNN Tromsø, the only hospital in the area. In the period 
1969-1979, the International Classification of Diseases (ICD) version 8 codes 410-414, 427, 
795-796, from 1980 to 1998, ICD version 9 codes 410-414, 798, 427.5 and thereafter ICD 
version 10 codes I20-I25, R96, R98, R99, I46 were used. The National Causes of Death 
Registry allowed identification of fatal cases of MI that occurred as out-of-hospital deaths. 
For event ascertainment the endpoint committee followed a detailed protocol and examined 
all available medical records, including medical records from other hospitals and prehospital 
records from ambulance service, general practitioners, nursing homes and death certificates. 
Modified WHO MONICA/MORGAM (MOnica Risk, Genetics, Archiving and Monograph) 
criteria were used and included clinical symptoms and signs, findings in ECGs, values of 
cardiac biomarkers, and autopsy reports when applicable (158). Biomarkers considered were 
CK, its myocardial fraction (CK-MB) (from 1990), and cTnT beginning in 1999. Biomarker 




onset. Biomarker increases associated with revascularization procedures were not included 
as MI. Silent MIs as defined by ECG only were not included as cases because of difficulties in 
determining the exact date of the event. We classified hospitalized STEMI and NSTEMI by 
using standard criteria (52, 53). Out-of-hospital SCD was defined as death caused by a 
probable MI (based on symptoms or autopsy) within 24 hours of symptom onset in non-
hospitalized individuals, or deaths in individuals brought to hospital with a cardiac arrest and 
unsuccessful resuscitation with no evidence of a non-coronary cause of death. Case fatality 
was defined as the proportion of incident CHDs that were fatal within 28 days or 1 year. 
Trends in MI severity (1995–2010) were evaluated by calculating the proportion of events 
with new Q-waves or ST-segment elevation in ECG, and the peak CK values.  
 
3.4 Coronary risk factors measurements used in paper 2 
 
Each survey used a standardized and almost identical protocol including physical 
examination, blood sampling, and questionnaires. Blood pressure and heart rate were 
measured with an automatic device (159). The average of the last two measurements was 
used. Height and weight were measured with subjects wearing light clothes and no shoes. 
Body Mass Index (BMI) was calculated as weight in kilograms divided by the square of height 
in meters (kg/m2). Nonfasting blood samples were analyzed (for total cholesterol, HDL 
cholesterol) by standard methods at the UNN Tromsø (159). Smoking status and diabetes 
mellitus was self-reported in a questionnaire. Participants were defined as physically active if 






3.5 Data registrations used in paper 3 
 
Data were obtained from a prospectively collected registry at UNN Tromsø organized by an 
experienced cardiologist. The registry included data from prehospital PHT forms, written 
records from ambulances and the UNN Tromsø Emergency Department and cardiac care 
unit, and reports from coronary angiography and PCI. We collected demographic data, times 
for symptom onset, ambulance arrival, pre-hospital ECG, start of “MONA” (morphine, 
oxygen, nitroglycerine, acetylsalicylic acid) and PHT, out-of-hospital cardiac arrest (OHCA), 
arrival at emergency department and cardiac care unit and time of coronary angiography 
and PCI at UNN Tromsø. Appropriateness of PHT, adverse PHT-events, in-hospital 
echocardiography, ECG, biomarkers, and patient discharge diagnosis were recorded. We 
defined “systolic heart failure” as LVEF < 40 %. Major bleeding was defined according to 
Bleeding Academic Research Consortium (BARC) type 2-5 bleeding (160). The date of death 
was obtained from the national Central Norwegian Population Register for calculation of 1-
year case fatality. To investigate possible time trends, the study was divided into three time 
periods; 2000-03, 2004-07, and 2008-11. We have incomplete data on STEMI patients not 
treated with PHT (i.e. primary PCI), because a local registry of invasive cardiology was not 
established before mid-2000 with initially insufficient data. 
 





For incidence analysis, we used the split function in STATA 10 (Stata Corp LP, College Station, 
TX) to produce a new record for each follow-up year for each person. Years were adjusted to 
a 365.25-day length and age was updated on the first of July in every year the participants 
were being followed up. The MI incidence rates were calculated by dividing the number of 
all events over a period of time by the corresponding person-years at risk. To account for 
non-linear time trends, calendar year was fitted using fractional polynomials and regressed 
on MI incidence and case fatality in Poisson and logistic regression models, respectively. All 
analyses of incidence rates and case fatality were age adjusted by including age as a 
continuous variable in the regression models, and stratified on sex and age (35–49 years, 
50–64 years, 65–79 years and 80 years and older). Differences in hospitalized MI severity 
across time (2000–4 compared to 1995–99) were assessed by logistic regression for binary 
severity indicators (new Q-wave or ST-segment elevation in ECG) and linear regression for 
the natural log of peak CK, adjusted for age and sex. Trends across age and between sexes 
were compared by including two-way interaction terms between year and age and year and 
sex.  
 
3.7 Statistical analyses in paper 2 
 
Statistical analyses were performed with STATA 12 (Stata Corp LP, College Station, TX) and 
SAS 9.3 (SAS Institute, Cary, NC). Age- and sex-adjusted means or prevalence of risk factors 
over time was estimated from generalized estimating equations to account for dependencies 
between repeated observations. The identity and logit link functions were used for 




use of the mean value for age and sex (57.9 years and 46% male) in the regression models. 
Hazard ratios of CHD for coronary risk factors were estimated with Cox proportional hazards 
regression adjusted for age and sex. Hazard ratios of subtypes of CHD were estimated with 
the augmented data approach (161). For incidence analysis, we used the split function as in 
paper 1. Time trends in event and mortality rates and case fatality proportions were age and 
sex standardized with the Tromsø population in 2007 used as the standard population for 
the first 2 end points and the CHD event cohort for the last end point. The CHD mortality 
decline explained by out-of-hospital SCDs was estimated as the difference in out-of-hospital 
SCD rate between 2010 and 1995 divided by the difference in total CHD mortality rate 
between 2010 and 1995. The proportion of the CHD mortality decline that was explained by 
the decline in incidence rates or case fatality was calculated as in the MONICA study: the 
average annual change in mortality rate is the sum of the average annual changes in event 
rate and case fatality proportion, expressed as percentages (46). Poisson regression models 
were used to estimate linear time trends in events. The proportion of the CHD incidence 
decline that was explained by change in each risk factor was estimated by the expression 
(β0−β1)/β0, where the βs are time-trend coefficients from Poisson regression models, the 
former adjusted for age and sex and the latter with additional adjustment for risk factors 
added to the model as time-dependent covariates. End of follow-up was defined as 2001 for 
those who did not attend the 2001–2002 survey and as 2007 for those who did not attend 
the 2007–2008 survey. Individuals who had a CHD event were censored from the analyses at 
the time of their event. One thousand bootstrapped samples were simulated (with 
replacement) to estimate the 95% confidence interval (CI) for the explained decline.  
 









percentile) or percentages. The chi-squared 
test was used for comparisons of binary variables. We used logistic regression models for 
categorical variables to estimate linear time trends and either linear regression models or 
non-parametric tests (Jonckheere trend test) for continuous variables. All statistical analyses 
were done using STATA 14 (StataCorp LP
®
















4. Summary of results 
4.1 Paper 1 
 
From 1974 to 2004, a total of 1669 incident MIs occurred among the 31,323 participants 
during a total follow-up time of 400,572 person-years. Seventy-one percent of incident MIs 
occurred in men. The mean age at the time of the MI event was 62 years for men and 73 
years for women. Seventy-nine percent of all events were treated in hospital, whereas 15% 
of all events were out-of-hospital deaths. The overall 28-day case fatality was 32%.  
 
Trends in the incidence of MI differed significantly by sex and age. From 1995 to 2004 the 
age-adjusted incidence of MI in participants of 35–79 years declined by 26% in men, but 
increased by 61% in women. In both genders, MI incidence among patients over 80 years did 
not change. Temporal trends in the incidence of MI did not change notably when troponin-
only cases were excluded. 
 
From 1995 to 2004 the age-adjusted odds of death within 28 days fell significantly by 52 % 
among men and by 59% among women aged 35–79 years. For patients older than 80 years, 
case fatality decreased significantly in men, but not in women. Among patients younger than 
50 years of age, case fatality did not change in men whereas in women there were too few 
cases for analysis. Furthermore, there was a significant 52 % decline in the odds of 1-year 






In all hospitalized patients with MIs between 1995 and 2004, the proportion with Q-wave 
pattern on ECG decreased significantly, as did the peak CK level, and a similar trend was 
observed for the frequency of ST-segment elevation in ECG. Furthermore, the 28-day case 
fatality declined significantly. The trends in case fatality, ECG findings and CK were similar in 
men and women and across all age groups, and also when cases meeting only troponin 
criteria were excluded. Among all hospitalized MIs between 1995 and 2004, the use of 
revascularization (PCI and/or CABG) within 28 days and the use of aspirin, β-blockers and 
statins at dismissal increased markedly over time. 
 
4.2 Paper 2 
 
We identified 1845 patients (39% women) with an incident CHD event between 1995 and 
2010, representing a period of 375 064 person-years. Seventy-eight percent of the patients 
(n=1441) were hospitalized. Among those were 523 patients (36%) with STEMI, 869 (60%) 
with NSTEMI, and 49 with unclassifiable MI. A total of 236 hospitalized patients (16%) died 
within 28 days. Among the 404 nonhospitalized patients, there were 332 out-of-hospital 
SCDs and 341 deaths within 28 days after symptom onset. Thus, 58% of all fatal incident CHD 
events occurred as an out-of-hospital SCD. 
 
The age- and sex-adjusted incidence of total CHD decreased by 3% each year. This decline 
was driven by decreases in out-of-hospital SCD (annual decline 7.6%) and hospitalized STEMI 
(annual decrease, 4.3%). In contrast, hospitalizations for NSTEMI increased in the first half of 





Favorable changes in coronary risk factors during the study period accounted for 66% of the 
decline in in the incidence of total CHD. Favorable changes in cholesterol contributed 32% to 
the decline, whereas blood pressure, smoking, and physical activity each contributed 14%, 
13%, and 9%, respectively. Increases in BMI and the prevalence of diabetes mellitus were 
associated with 7% and 2% increase in the risk of CHD, respectively. 
 
The age- and sex-standardized CHD mortality rate fell by 7.3 % annually, and case fatality by 
4.0 % annually. Thus, changes in incidence and case fatality contributed 43 % and 57 %, 
respectively, to the decline in CHD mortality. Furthermore, 65 % of the decline in CHD 
mortality was attributable to a decrease in the rates of out-of-hospital SCDs.  
 
Peak CK levels decreased significantly in patients with NSTEMI, and the proportion of 
patients who developed Q waves on ECG decreased significantly over time among patients 
with both STEMI and NSTEMI. Revascularization and the proportion of patients receiving β-
blockers, acetylsalicylic acid, and statins at discharge increased over time. Age- and sex-
adjusted 28-day case fatality decreased by 26% (not statistically significant) in STEMI 
patients and by 43% in NSTEMI patients in 2005 to 2010 compared with 1995 to 1999.  
 
4.3 Paper 3 
 
Successful ECG-transmission from ambulances to UNN Tromsø were completed in 99 %, and 




inferior wall MI accounted for 46 % and 43 %, respectively, UAP 3 %, while 8 % did not suffer 
from ACS and should not have been given PHT. Median age was 61 years and 77 % were 
male. The median time from onset of chest pain to ECG was 110 minutes and the median 
time from first prehospital ECG (a proxy for FMC) to start PHT was 36 minutes. The median 
time from symptom onset to PHT was 150 minutes, and 31 % of patients received PHT within 
120 minutes. Median evacuation time to UNN Tromsø following PHT was 93 minutes, whilst 
the median time from hospital admission to primary PCI (‘door-to-balloon’) has been 
estimated to 38 minutes (162). Thus, the early prehospital diagnosis and thrombolytic 
therapy may have saved 2 hours 11 minutes to initiation of reperfusion therapy. The 
majority (82 %) of patients underwent coronary angiography within 24 hours, and a total of 
69 % received PCI while 10% underwent CABG during hospital stay. 
 
The proportion of patients who received PHT within two hours after symptom onset 
increased from 21 % in 2000-03 to 39 % in 2008-11, whilst the proportion of patients 
receiving inappropriate PHT fell from 14 % to 2 % in the same period. The proportion of 
patients receiving thrombolytic therapy who had coronary angiography or PCI within 24 
hours of FMC increased from 56 % to 95 %. Based on our local registry of invasive cardiology, 
an increasing number of STEMI patients received primary PCI from 2006 to 2011, while the 
proportion treated with PHT declined from about 40% to 30% (data not shown). The one-
year mortality rate among patients treated with PHT fell from 11 % in 2000-03 to 6 % in 
2008-11 (not statistically significant), whilst the proportion who developed systolic heart 
failure (i.e. LVEF <40%) decreased significantly over time from 19 % in 2000-03 to 8 % in 
2008-11. Maximum cTnT levels decreased significantly over time. Among the 355 patients 




ST-segment resolution. One-year mortality was 4 % and 11 %, respectively. We lack 
information about ST-segment resolution in 30 patients (8 %). Based on our registry of 
invasive cardiology, 35 % of PHT-treated patients received rescue PCI during 2006-2011. 
Thirteen (3 %) of the 385 patients suffered acute OHCA with ventricular fibrillation. All of the 
13 patients received successfully out-of-hospital resuscitation with a return of spontaneous 
circulation (ROSC) on hospital admission, and 12 of the 13 patients were discharged alive. 
Three of the patients given PHT (0.8 %) developed cardiogenic shock and died before 
reaching hospital. Ten patients (2.6 %) suffered a major bleeding: eight had gastrointestinal 
or groin bleedings after PCI, two required a transfusion of at least two units of blood. Two 














5. Discussion – methodology 
5.1 Study classifications in epidemiological and clinical research 
 
Studies can be classified into descriptive and analytic studies. Descriptive studies are always 
observational studies and describe general disease characteristics related to person, place, 
and time. They include cross-sectional studies, and case series (3, 163). Analytic studies test 
a hypothesis about a causal relation between exposure and outcome. They can be 
observational, such as case-control and cohort studies, or controlled, such as the 
randomized controlled trial (RCT) (3). The results of RCTs are considered the highest level of 
evidence because randomization controls for prognostic factors between two comparison 
groups, thereby minimizing the role of confounding bias and optimizing the internal validity.  
 
5.2 Study design in paper 1 and 2 
 
The Tromsø Study is a prospective cohort study, as individuals are screened for risk factors 
prior to disease and followed up by repeated screenings. A cohort study tracks two or more 
groups forward from exposure to outcome. The temporal sequence between putative cause 
and outcome is usually clear: the exposed and unexposed can often be seen to be free of the 
outcome at the outset. All participants are followed up with regard to mortality and disease 
incidence. A cohort study is the best way to identify incidence and natural history of a 
disease. Research purposes are to study natural history of disease, measure incidence, and 





5.3 Study design in paper 3 
 
A (clinical) case-series is a study that follows a group of patients who have a known 
exposure, such as a similar diagnosis or who are undergoing the same procedure over a 
specific period of time. Case series may be consecutive (164) or non-consecutive (165), 
depending on whether all cases over a period were included, or only a selection. Research 
purposes in case-series are to study signs and symptoms, create disease definitions, 
surveillance of mortality/morbidity rates, and seek associations (3). Case series are often 
used to describe outcomes of novel treatments. The information gained can be used to 
generate hypotheses that lead to focused studies of a stronger design. They are also helpful 
in refining new techniques or treatment protocols before they are studied in more advanced 
trials (166). Distinguishing cohort studies from case series can be difficult. They share a main 
design feature of having a follow-up period examining the exposed individuals over time. 
The major difference between cohort studies and case series in many definitions is that 
cohort studies compare different groups (i.e., examine the association between exposure 
and outcome), while case series do not include a comparison group. (167). 
 
5.4 Weaknesses of observational studies 
 
Results of observational studies are susceptible to the effects of chance (random error), bias 




conclude the existence of a valid statistical association when one does not exist (type 1 
error) or alternatively the absence of an association when one is truly present (type 2 error) 
(3). Random errors give imprecise study results and can be minimized with large sample 
sizes. The relatively small number of study patients is therefore a weakness in paper 3. The 
role of chance can be assessed by performing appropriate statistical tests to produce a p-value and by 
calculation of confidence intervals. Statistical methods only assess the effect of sampling variation and cannot 
control for non-sampling errors such as confounding or bias in the design, conduct or analysis of a study. 
Systematic errors give inaccurate study results, a deviation of results from the truth, and 
increasing the sample size is not going to help. Types of bias can broadly be grouped into 
two categories: selection bias and information bias.  
 
5.5 Selection bias 
 
Selection bias occurs when there is a systematic difference in the characteristics between 
those who are selected for a study and those who are not (3). A selection bias comes from 
any error in selecting the study participants and/or from factors affecting the study 
participation. As a consequence, the relationship between exposure and disease differs 
between those included in the study and those potentially eligible for the study (including 
non-participants or non-responders).  
 
Participation in the Tromsø Study is voluntarily, and although the general participation rate 
is high, there is a possibility for selection bias. Local restrictions given by the Norwegian Data 
Inspectorate preclude detailed analyses of mortality and morbidity according to attendance. 




proportion of men and single (156). Furthermore, participants in cohort studies may be 
healthier than the general population (159). To explore this further, we will describe 
differences in risk factor values in the survey undertaken in 1994-95 between those who 
attend subsequent examinations (in 2000-01 and/or 2007-08) and those who did not attend 
(table 3).  
 
Table 3 Risk factor levels in 1994-95 among subjects who were invited but did not attend 




































            
Invited, did 
not attend 
2448 46.1 51 6.11 1.48 138 25.3 47 1,9 76 29 
Invited, 
attended  
12676 49.3 45 6.20 1.53 135 25.4 34 1,4 73 30 
 
 
Non-attenders in later surveys were likely to be younger men with slightly higher risk profile 
than attenders in later surveys. Nevertheless, the main impression is that the difference is 
not substantial. We believe that participants in the Tromsø Study are representative of the 





Loss to follow-up (because of death, disability, relocation, or drop-out) can be a difficulty, 
particularly so with longitudinal studies that continue for decades. Differential losses to 
follow-up between those exposed and unexposed can bias results (163). However, loss to 
follow-up is not of a major concern in the Tromsø Study. The national 11-digit unique 
personal identification number facilitates complete follow-up by allowing linkage to disease 
registries, the cause of death register, and the Norwegian Patient Registry. The Population 
Register of Norway registers emigration from the municipality and date of death. The 
University Hospital of North Norway is the only hospital in Tromsø, admissions to other 
hospitals are unlikely because of long distances.  
 
Case-series are susceptible to bias, particularly selection bias. Case-series draw their patients 
from a particular population (such as a hospital or clinic), which may not appropriately 
represent the wider population. However, a population case-series study, consisting of a 
complete set of cases in a defined population (or catchment area) and time, lays the 
foundation for description of disease by place, time, and characteristics of population (3). 
This is possible for rural areas with small populations and a single healthcare provider, as in 
our study. Furthermore, our study contains several key criteria that constitute a well-
designed case series, which will help limit selection bias (166, 168). The study had clear 
objectives with a well-defined, a priori study protocol. The inclusion and exclusion criteria 
where explicitly stated, and there were no patients loss to follow-up. However, one 
weakness is that the list of cases may be incomplete, i.e. cases were not consecutively 
selected. We cannot preclude that some prehospital deaths are missing. Additionally, over 




PHT and primary PCI groups may differ in characteristics that affect the study outcome. The 
risk of selection bias is therefore present and requires caution in comparing between time 
periods.  
 
5.6 Information bias 
 
Information bias refers to bias arising from measurement error, i.e. when key study variables 
(exposure, health outcome, or confounders) are inaccurately measured or classified. This 
may mean that study participants are placed in the wrong exposure- or outcome category, 
leading to an incorrect estimate of the association between exposure and outcome (3, 169). 
Misclassification may be introduced by the observer (observer bias), by the study participant 
(responder bias) or by measurement tools such as questionnaires or instruments such as 
weighing scales or blood pressure cuffs (instrument bias). There are two types of 
misclassification – differential and non-differential.  
 
Non-differential (random) misclassification occurs if there is equal misclassification of 
exposure between subjects that have or do not have the health outcome or if there is equal 
misclassification of the health outcome between exposed and unexposed subjects. Non-
differential misclassification increases the similarity between the exposed and non-exposed 
groups, and may result in an underestimate (dilution) of the true strength of an association 
between exposure and disease, i.e. a “bias towards the null”. Differential (non-random) 




exposure. This type of error is considered a more serious problem, as one of the groups is 
more often misclassified than the comparison group and this may introduce bias.  
Differential misclassification may be introduced in a case control study as a result of recall 
bias or observer/interviewer bias. In cohort studies like the Tromsø Study there is little room 
for differential misclassification, as the relevant data on exposure(s) are collected at baseline 
(without knowledge on outcomes) using standardized methods. 
 
Non-differential misclassification is more common in cohorts and may occur in this thesis 
due to incomplete medical records or questionnaires. Study participants may have 
difficulties to remember past exposure when completing questionnaires, or questions could 
be misunderstood or skipped. In addition, some of the participants will not know that they 
have the condition that is being requested. An example is diabetes mellitus, which is defined 
based on self reporting in the Tromsø Study. This may explain why the prevalence of 
diabetes mellitus type 2 is markedly reduced in the Tromsø Study compared with the general 
population (170). Another example of self-reporting bias is social desirability bias when 
participants answer in a way to portray themselves in a good light. It is important to use 
questionnaires that are constructed to maximize accuracy and completeness. The most 
precise and accurate measures of exposure and outcome will protect against random 
misclassification producing a type 2 error.  
 
Classification of individuals (exposure or outcome status) can be affected by changes in 
diagnostic procedures. To control for information bias, it is important to implement 




in paper 1 and 2 is the introduction of troponin as markers of myocardial injury, a marker 
not included in the MONICA criteria for validation and classification of MI events. This means 
that MI definition before and after the year 2000 differs somewhat. The true effect of 
changes in diagnostic sensitivity of biomarkers could not be fully quantified. However, the 
potential bias from this would be an overestimation of the incidence of NSTEMI in later 
years. The use of three different ICD classification systems during the 36-year period should 
not be a bias since the codes only have been used to collect possible cases. Accurate coding 
of cause of death may represent a challenge in individuals dying outside of hospitals. In our 
material, only 9 % of individuals with out-of-hospital SCDs underwent medical autopsy. As 
there have been no changes in registering causes of deaths during the study period it is likely 
that misclassification did not change over time, and therefore did not affect our trend 
analyses.  
 
The term reliability refers to the precision and reproducibility of the data collected. There 
are several ways to enhance reliability: using clearly defined diagnostic criteria, standardizing 
the measurement methods, training and supervision of observers, calibrated equipment, 
repeating the measurement and using the mean of two or more readings (169). LVEF is one 
of the most commonly reported measures of LV systolic function. Prognosis and therapeutic 
decisions are often based on LVEF, which means the LVEF needs to be accurately measured. 
Many imaging modalities can measure LVEF (echocardiography, cineventriculography, 
magnetic resonance imaging [MRI], computed tomography [CT], multiple-gated 
acquisition[MUGA], and gated myocardial perfusion imaging with either single-photon 




of these modalities is subject to measurement errors that can lead to the inaccurate 
calculation of LVEF. Currently, there is no universally accepted “gold standard” for measuring 
LVEF. With any method, the endocardial border needs to be accurately detected to ensure 
accurate LV cavity detection and LVEF calculation.  
 
Echocardiography, used in paper 3, is the most frequently used imaging modality for the 
evaluation of LV volumes and function. The biplane method of disks (modified Simpson 
method) is a 2-dimensional echocardiographic technique requiring tracing the LV 
endocardial border in the apical 4- and 2-chamber views in both end-diastole and end-
systole. This is the method recommended by the American Society of Echocardiography for 
measuring LVEF (171). LVEF measurements at UNN Tromsø was done primarily by the 
Simpson’s volumetric method whenever possible, or by 2-dimensional visual estimation. 
Visual assessment of the LVEF and segmental wall motion requires extensive skill and 
expertise of the reader and ultimately remains subjective (172). Additionally, 2-dimensional 
assessment of global LV volumes and EF with the biplane method of discs relies on 
geometric assumptions and is subject to plane positioning errors. More important, all these 
methods of LV assessment are known to have limited inter-observer and test–retest 
reliability (173-176). For an instrument such as 2-dimensional echocardiography to be useful 
in clinical practice, it needs to yield similar results when applied by different users and at 
different times. In our study, all measurements and analyses were performed by 
experienced physician echocardiographers, but without a standardized protocol for 
examination techniques and measurement procedures, and the interobserver variability 







Confounding bias occurs in the presence of confounders, that is, factors that distort the true 
relationship of the study variable of interest by also being related to the outcome of interest 
(177, 178). In order for a variable to be considered as a confounder the variable must be 
independently associated with the outcome (i.e. be a risk factor), and the variable must be 
associated with the exposure under study in the source population, and finally, it should not 
lie on the causal pathway between exposure and disease. Confounding involves the 
possibility that an observed association is due, totally or in part, to the effects of differences 
between the study groups (other than the exposure under investigation) that could affect 
their risk of developing the outcome being studied. The consequence of confounding is that 
the estimated association is not the same as the true effect. The potential for confounding 
should be considered in the design and implementation of the study. Factors which might be 
associated with the outcome other than the putative risk factor/exposure need to be 
measured. To some extent, confounding can be accounted during analysis with stratification 
or mathematical modeling such as multiple logistic regression, assuming that such factors 
have been measured as part of the study. In our studies, we used regression models to limit 
possible confounding. Confounding bias is not present in case series for the simple reason 
that there is no control group (168). However, when analyzing time trends in observational 
studies, there is always a possibility that other external factors change over time and 
thereby confound the results. In paper 3, a healthier population joining the registry late 







Validity is used in epidemiology to assess the degree to which the information collected 
accurately answers the research question; i.e., the extent to which the results are accurate 
and the extent to which the conclusions derived can be generalized (Zaccai). Internal validity 
refers to whether the results are representative for the population under study. Selection 
bias, information bias, uncontrolled confounding, or an unduly small study sample may 
impair internal validity. External validity is to what degree the results of a study are 
generalizable to a broader population beyond the study population. Internally validity must 
be established before one can consider whether the results are externally valid. 
 
As most RCTs have strict criteria for participants included in the trial, the external validation 
is often questioned. In a cohort study with a large number of participants from the general 
population and minimal loss to follow up, like the Tromsø Study, there will be a high degree 
of generalization, increasing the external validity of the study. Case-series, as in paper 3, 
have apparently high external validity with no interference in treatment decision process 
and a wide range of patients. However, internal validity of case series studies is usually low, 
due to the lack of a comparison (control) group exposed to the same array of intervening 
variables. Conducting a case series prospectively or retrospectively makes a difference as to 
the extent of selection and measurement bias in the observations. A retrospective design 
may decrease the completeness of inclusion, data collection, and patient follow-up. 








Statistical associations do not necessarily imply causal associations (3). Spurious associations 
are the result of selection bias, information bias, and chance. By contrast, indirect 
associations (which stem from confounding) are real but not causal. Criteria which ought to 
be fulfilled before assuming causality were drawn up by Hill in 1965 (180). Briefly, these 
criteria require a consistent body of evidence to have accumulated. The most robust 
criterion is temporality: the cause must antedate the effect. Strong associations (relative 
risks more than 3), and evidence of a biological gradient (dose-response relation) supports a 
causal association too. A single epidemiological study is never sufficient to determine a 
causal relationship.  
 
Case series have a descriptive study design. Unlike studies that use an analytic design (e.g. 
cohort studies or RCT), case series do not usually involve hypothesis testing to look for 
evidence of cause and effect. Case series reports on data from a subject group without a 
comparison (control) group. A control group is a group of patients who share all of the 
characteristics of the patients of the treatment group except that they do not receive the 
treatment. When a study lacks a control group, no causal inferences should be made about 
the relationship between the treatment and the outcomes, since it is impossible to 
determine whether the outcomes are attributable to the treatment effect or to other 
patient characteristics (168). The effects seen may be wholly or partly due to intervening 
effects such as the placebo effect, time effects, practice effects or the natural history effect. 




designed case series can provide information that allows hypotheses to develop, leading to 
further advanced studies. Treatment safety and diagnostic accuracy are the principal 



















6. Discussion – results 
6.1 Declining incidence trends in men, not in women in the time period 1974 -2004 
 
Temporal trends in MI incidence between 1974 and 2004 differed markedly by sex and age. 
Among persons below 80 years of age, MI incidence decreased in men and increased in 
women, whereas in persons aged ≥80 years the trends remained stable in both genders. 
Comparisons with results from other studies should be done with caution due to possible 
methodological differences. However, our results are in line with findings in some other 
populations, both incidence studies (114-118) and prevalence reports (119, 181). A decrease 
in the incidence of CHD events is mainly considered to be due to favourable risk factor 
development in the population. The WHO MONICA Project has monitored coronary risk 
factors in 38 populations from 21 countries in four continents over a 10-year period (182). 
The study found that cholesterol levels, and the blood pressure levels and the treatment of 
elevated blood pressure improved in both genders (182). The prevalence of smoking 
declined among men, whereas no decline or even an increasing trend was observed in 
women (182, 183). The proportion of daily smokers among Norwegian men fell from 51% in 
1974 to 27% in 2004, but fell less in women (from 32 to 25%) and even increased slightly in 
some age groups (from 22 to 25% in the age group 55–64 years and from 10 to 15% in age 
group 65–74 years) (figure 1) (184, 185). Data from the Tromsø Study surveys show similar 
trends (186). Exposure to tobacco smoke has been found to be a stronger risk factor for MI 
in women than in men (184, 187, 188). In one study, first MI occurred significantly earlier in 
female smokers compared to male smokers, implying that twice as many years were lost by 




smoking among young and middle-aged women may be a partial explanation for the present 
findings. Other possibilities include obesity and diabetes, which have increased in both 
genders, but diabetes is known to be a stronger risk factor for CHD in women than in men 
(189). The AHA and the ESC have focused special attention on women's cardiovascular 
disease (29, 190). The rationale is that the cardiovascular risk may have been 
underestimated in women, which in turn may have led to insufficient prevention and 
treatment efforts in women. 
 
An obvious question is whether the differences in MI event trends between men and women 
reflect real occurrence of the disease or whether they reflect increased detection of events 
that formerly went unrecognized. ACS patients presenting without chest pain are frequently 
older and more likely to be women (191). However, recent surveys of the general public in 
the US indicate that the awareness of heart disease in women has increased in recent years 
(192, 193). It may be that women with chest discomfort during the follow-up period in our 
study have been more inclined to seek health advice, and that some of the increasing 
incidence is due to detection bias. Furthermore, the greater sensitivity of troponins may help 
in finding those acute MIs where the patient presents to the clinician with less obvious acute 
coronary symptoms. Women with ACS have a higher prevalence of unstable angina rather 
than MI, more frequent NSTEMI than STEMI, and a higher likelihood of having clinically 
insignificant disease on coronary angiography (194, 195). Previously studies have shown that 
the adoption of troponins has caused a greater increase in MI diagnoses among women than 
among men (60). It is, however, unlikely that the adoption of troponins could explain the 
gender by age group interaction observed in the present study. The trends did not differ 




Furthermore, the trends were emerging before the introduction of troponin in 2000 (Figures 
1 and 2 in paper 1). In our study, 5% of the cases with troponin measurements met only 
troponin-based criteria. This figure is smaller than in comparable studies (59), probably due 
to incomplete implementation of the new criteria in clinical practice (57, 64). 
 
6.2 Outcome and treatment similar in men and women 
 
In contrast to these opposing incidence trends, we found similar reductions among men and 
women in 28-day and 1-year case fatality and in the severity of first MI as evaluated by 
biomarkers and ECG. This is in line with results from other studies (59, 67, 117). Among all 
incident MIs, we found a 52 % decline in the age- and sex-adjusted odds of 1-year case 
fatality between 1994 and 2004. Furthermore, we found a substantial decline in the severity 
of hospitalized first MIs as evaluated by both biomarkers, ECG (Q-waves and ST-segment 
elevation), and 28-day case fatality. Notably, these changes were not related to the 
introduction of troponin measurements.  
 
The consistency across MI severity indicators supports the robustness of the trends, and the 
hypothesis of declining MI severity over time. Possible explanations may be improved risk 
factors levels, more sensitive biomarker diagnostics, and advances in evidence-based 
treatments (increased use of aspirin, statins, b-blockers and revascularization). It is likely 
that the decline in MI severity is a major determinant of the decline in case fatality in the 




delay between the onset of symptoms and hospitalization, which may confound any 
association between calendar year and MI severity. However, time to admission did not 
change over time in two comparable studies (59, 67). Case fatality has been reported to be 
higher among women compared with men, possibly due to differences in the level of acute 
coronary care (196). However, we found no significant gender differences in MI severity or 
case fatality and no gender differences in the use of invasive revascularization or 
medications.  
 
6.3 Declines in out-of-hospital sudden death and STEMI 
 
We found that that age- and sex-adjusted incidence of total MI decreased by 3% annually 
over a 15 years of follow-up between 1995 and 2010). The decrease was driven by a 50% 
reduction in severe MIs, i.e. SCDs outside hospitals and hospitalized STEMI infarction. 
Substantial reductions in serum cholesterol accounted for approximately one-third of the 
event decline, but decreases in smoking, blood pressure, and heart rate and increased 
physical activity all contributed. Overall, risk factors accounted for 66% of the decline in 
incidence of hospitalized and nonhospitalized fatal and nonfatal MI. Interestingly, increases 
in body mass index and diabetes mellitus were associated with modest increases in disease 
outcomes. This study extends results of previous studies that found modifiable risk factors to 





The study demonstrates that primary prevention by modification of risk factors by means of 
a healthy lifestyle or medication will influence both incident CHD and case fatality in 
populations, shown by the association between coronary risk factors and out-of-hospital 
sudden deaths. Thus, sudden death is a preventable condition (20, 197, 198). Studies have 
shown that the majority of the SCD victims in the community had severe subclinical CHD, 
and that traditional coronary risk factors were prevalent and under-treated (20). In our 
study, higher resting heart rate was more strongly associated with out-of-hospital sudden 
death than with STEMI or non-STEMI (Table 2 in paper 2). Higher heart rates are associated 
with myocardial ischemia, ventricular arrhythmias, and coronary atherosclerosis (199-201). 
Correspondingly, we found that physical activity, which lowers resting heart rate, was 
associated with a lower risk of out-of-hospital sudden death and accounted for 9% of the 
decline in total CHD.  
 
We found that cardiovascular risk factors had different impacts on subtypes of CHD, 
suggesting that the spectrum of CHD manifestations among populations and over time may 
differ, depending on the relative prevalence of the risk factors. Our findings suggest that 
reduced prevalences of hypercholesterolemia and smoking are major driving forces for the 
decline in the incidence of STEMI, indicating that primary prevention efforts result in fewer 
severe events (59, 67). In line with this, others have found that cholesterol is associated with 
rupture of vulnerable plaques and that smoking is associated with coronary thrombosis 
(197). In a large survey of patients with ACS from 25 countries in Europe and the 
Mediterranean basin, it was found that smoking was related to patients presenting with 




acetylsalicylic acid) has increased over time, and these agents may have beneficial effects 
beyond their effect on risk factors and may contribute to a lower severity of subsequent 
cardiac events (203-205). The prevalence of selfreported angina pectoris fell by 29% (Table 3 
in paper 2), suggesting that risk factor changes led to the less coronary atherosclerosis. 
 
How quickly might population health benefits follow improvements in population risk factor 
levels? The analysis was based on the assumption that the effects of changes in risk factors 
on CHD outcomes occurred within the time between consecutive surveys (≈6 years) or 
between the last survey and 2010 (≈3 years). This might underestimate the effects of a risk 
factor change if a lag time of >3 to 5 years is present before the benefits of a risk factor 
change are realized. However, extensive empirical and trial evidence shows that substantial 
reductions in mortality can occur within months of decreases in smoking, and within 1–3 
years of dietary changes (206-209). This reduction applies to both individuals and to entire 
populations.  
 
The substantial decline in CHD mortality was driven by significant reductions in the incidence 
of out-of-hospital SCD and hospitalized STEMI and by a significant reduction in case fatality 
among hospitalized patients. The decline in event rates and the decline in case fatality each 
explained 50% of the decline in CHD mortality. We observed that three out of five fatalities 
represented out-of-hospital deaths. In line with others, we found that changes in the rates of 
out-of-hospital SCD had a stronger impact on CHD mortality trends than changes in mortality 
of hospitalized patients (105, 210). In contrast, a study from Sweden based on administrative 




Many fatal events still occur out of the hospital in spite of the improvement in CHD mortality 
and advances in CHD medical treatment, prevention, and emergency transport systems (15, 
210, 211). It is therefore of concern that the time from onset of chest pain to arrival at the 
hospital has not improved despite community education efforts (212). To achieve further 
reduction in CHD-related case fatality, primary prevention is increasingly more important, as 
are efforts to convince individuals to seek hospital treatment as soon as symptoms of a 
major coronary event occur. 
 
The decline in out-of-hospital and hospitalized MI incidence rates is consistent with data 
from recent international studies (11, 92, 102, 213). In Olmsted County, MN, between 1995 
and 2012, the population rate of MI declined 3.3% per year, with the greatest declines 
occurring for prehospital fatal MI (213). Both hospitalized case-fatality and out-of-hospital 
mortality decreased over time, as reported in other studies (11, 102, 104, 105). Sulo et al 
published in 2013 the first study to report trends in MI incidence for the whole Norwegian 
population, using data from all somatic hospitals in the country, as well as from the 
Norwegian Cause of Death Registry. They found that MI incidence rates declined during 
2001–2009, a decline that was due to reductions in rates of out-of-hospital deaths and 
hospitalizations in individuals 45 years or older (97). The patient administrative systems in 
Norway do not include information on MI subtype, so they were not able to examine 
whether the trends observed apply to both STEMI and NSTEMI. In line with other studies we 
found a declining percentage of MI cases with ST-segment elevation (59, 92, 96). In an 
analysis in the northern California, the percentage of MI cases with ST-segment elevation 




Sweden is a decline from 45% in 1995 to 27% in 2008 (84). As observed by others, we found 
an increasing incidence of NSTEMI in the first part of the study period (52, 92, 96), likely 
reflecting the use of more sensitive biomarkers that detect smaller myocardial necrosis. This 
is supported by declining peak CK levels among NSTEMI patients, whereas the levels were 
stable in STEMI patients. We believe that the decline in STEMI is real and that the initial 
changes in NSTEMI reflect increased diagnostic sensitivity. Reductions in case fatality rates 
for hospitalized MI are due, at least partly, to a decrease in the incidence of STEMI, a lower 
rate of death after NSTEMI, but also to the increasing detection of less severe MIs with 
troponin testing. Mortality at 28 days and 1 year after hospitalization for a first AMI declined 
in Norway between 2001 and 2009 in both men and women and in all age groups (214). 
 
6.4 Implementation and results following prehospital thrombolytic therapy 
 
An important finding of this study is that ambulance clinicians with the support of GPs and 
hospital cardiologists can safely and effectively perform PHT. Next, the study shows that the 
implementation of a decentralized PHT-system, combined with improved availability of 7/24 
invasive diagnosis and treatment-services, was gradual. The third important finding is that 
the adoption of evidence-based and guideline-recommended treatments was associated 
with significant reductions in time delays and earlier reperfusion therapy, and this was 
associated with a decline in left ventricular systolic heart failure visualized by 
echocardiography. This observation was supported by a significant decrease in peak cTnT 
levels over time. It has been found that cTnT-levels at a single point on any of the first 4 days 




magnetic resonance imaging (69). We routinely applied AED-defibrillation pads to the chest 
pain patients while administering MONA to enable the earliest possible defibrillation of any 
VF or pulseless ventricular tachycardia during diagnostics and thrombolytic treatment. Like 
others, we report an excellent outcome in STEMI patients suffering OHCA (215). 
 
The percentage who received PHT within 2 hours increased by 85 % (p=0.003) between 
2000-2003 and 2008-2011, to a total of 40 % in 2008-2011.  Thrombolytic therapy has best 
effect if given as soon as possible and within 2 hours after pain onset (124, 129, 130).  Early 
administration of PHT has been reported to be associated with improved 1-year survival 
compared with primary PCI (2.8 % versus 6.9 %, respectively; p=0.021) (132). In our study, 
one-year mortality for patients with ACS was 2.7 % if PHT was given within 2 hours, but 
increased significantly to 10.4 % if given later (p = 0.04). The “system delay” is the delay 
between FMC and reperfusion therapy, and it is more readily modifiable by organizational 
measures than patient delay. It is an indicator of quality of care and a predictor of outcomes 
(216). If the reperfusion therapy is thrombolysis, the goal is to reduce this delay (FMC to 
needle) to ≤30 min (8). In our study, the median time from first prehospital ECG (i.e. FMC) to 
start PHT was 36 minutes, and did not improve over time. It is important continuously to 
trim and maintain the system and to detect and remove the “time thieves”. The ECG 
transmission requires flawless technology and immediately available hospital physicians to 
confirm the STEMI diagnosis and decide on PHT without avoidable delays. 
 
The use of coronary angiography, PCI and CABG increased over time. The proportion of 




to 95% (p<0.001). The pharmacoinvasive strategy combining PHT and rapid transfer to 
planned PCI within 3-24 hours after ictus in hemodynamically stable patients and rescue PCI 
for failed thrombolysis, is an efficient reperfusion strategy for STEMI patients (133, 134). 
Randomized trials comparing PHT with primary PCI in patients who present early show no 
statistical difference in 30-day mortality or re-infarction (124, 217). Recently, the STREAM 
study also showed that the major cardiac events at 30 days following a pharmacoinvasive 
strategy in patients with FMC within 3 hours of symptom onset compared favorably with 
those of primary PCI performed beyond 60 minutes of diagnosis (128). The Norwegian 
NORDISTEMI-study suggests that an early invasive strategy may be the preferred option in 
patients receiving thrombolytic therapy, also in areas with long transfer distances (218). 
 
Ten patients (2.6 %) suffered a major bleeding, two patients (0.5 %) had intracerebral 
hemorrhage). In the latest trials, intracranial bleeding occurred in 0.9–1.0% of the total 
population studied (128). The percentage of inappropriate PHT-treatment dropped 
significantly during the study period from 13.6 % to 2.2 % (p=0.002), probably reflecting 
system maturation. The improved heart function and 1-year mortality may reflect the more 
widespread use of therapies proven in trials to lower the risk of complications and mortality. 
Analysis of data from the GRACE multinational observational cohort study of patients with 
ACS found evidence of an increased use of pharmacological (including β-blockers, statins, 
ACE inhibitors, and P2Y12 inhibitors) and interventional treatments over time. These 
practice changes were accompanied by significant decreases in the rates of in-hospital 
death, cardiogenic shock, recurrent MI, and heart failure among patients presenting with 




patients receiving β-blockers, acetylsalicylic acid, and statins at discharge increased over 
time. 
 
From 2000 to 2011, the post-MI systolic heart failure and 1-year mortality have been halved 
with an absolute reduction in systolic heart failure of almost 11 %. It should be noted, 
however, that this is an observational study and despite adjustments in the statistical 
models, no causality can be proven concerning the effect of changes of the treatment 
strategies. When analyzing time trends in observational studies, there is always a possibility 
that other external factors change over time and thereby confound the results. The study 
population might have included fewer high-risk patients at the end of the study. A similar 
trend has been seen in other studies and may be explained by improved primary and 
secondary prevention strategies (59, 205). Another explanation may be that an increasing 
proportion of STEMI patients over time received primary PCI instead of PHT. This is most 
likely linked to the implementation of evidence-based medical guidelines and an increase in 
the availability of coronary angiography and PCI. However, this treatment shift could affect 
the composition of the PHT population. Primary PCI may be a preferred reperfusion strategy 
for STEMI patients with heart failure, long duration of pain, and uncertain STEMI diagnosis. 
Thus, there is a risk of selection bias when comparing time periods. The observed trends in 
clinical outcomes and survival may be a combination of the fact that PHT really was given 
faster, that PHT treated patients received more and timely invasive investigation and 
treatment (pharmacoinvasive strategy), and that the proportion of primary PCI increased. 
Furthermore, time savings were estimated without a PCI comparison group for determining 




not admitted were not included. Patients’ dying before reaching the hospital might 























7. Conclusions and future perspectives 
 
In paper 1, we showed for the first time in Norway (157) that a substantial part of the 
decline in CHD mortality in the young and middle-aged population was due to a decreased 
incidence of the disease. The study indicates that the population burden of CHD may be 
shifting towards women and elderly patients, suggesting that preventive gains have not 
penetrated equally throughout the population. The severity and case fatality of the disease, 
however, was declining in all groups. 
 
In paper 2, we found that age- and sex-adjusted incidence of total CHD decreased by 3% 
annually over 15 years of follow-up. The decrease was found primarily in reductions in out-
of-hospital SCD and hospitalized severe myocardial infarctions (STEMI). Reductions in serum 
cholesterol accounted for approximately one-third of the event decline, and decreases in 
smoking, blood pressure, and heart rate and increased physical activity also contributed. 
Increases in body mass index and diabetes mellitus were associated with modest increases 
in disease outcomes. Overall, risk factors accounted for 66% of the decline in incidence. 
Furthermore, the decline in event rates and the decline in case fatality each explained 
roughly 50% of the decline in CHD mortality. This was partly explained by less severe disease 
in those afflicted, but also by a major improvement in treatment. 
 
In paper 3, we showed that ambulance clinicians with the support of GPs and hospital 
cardiologists could safely and effectively perform PHT. The implementation of a 




reperfusion therapy, and reduction in post-infarct systolic heart failure, and high survival 
rates among STEMI-patients suffering OHCA.   
 
The Tromsø Study showed declining trends in CHD incidence and case fatality over 35 years. 
To our knowledge, this is the longest population-based study published relying on individual 
person data and standardized data collection procedures. The combination of lower 
incidence and higher survival rate translates into a substantial improvement in mortality. 
Our study of MI incidence highlights the role of widespread prevention in contributing to this 
decline, because improvements in risk factors play a crucial role in the trends. This finding 
does not negate the effect of acute care and secondary prevention, both of which 
play important roles. The observed reduction in case fatality, is assumed to be attributed to 
closer adherence to guideline-based therapy. Continued efforts aimed at improving the 
translation of evidence-based interventions into routine practice are essential. 
 
We report changing secular trends in the relative proportion of STEMI and NSTEMI. If 
confirmed, this may have important implications for the ways that community and health 
care system resources are organized in the future, because current guidelines have 
extremely different recommendations for the short-term management of these two entities. 
It would be of interest to follow trends in incidence and case fatality further on, especially 
for STEMI. Recent National statistics have shown a continuing decline in CHD mortality. Can 
this partly be explained by ongoing declines in incidence and case fatality for STEMI?  
 
The substantial decline in out-of-hospital SCD rates has had a major impact on the favorable 




hospital. More effective prevention strategies and greater focus on information about the 
importance of seeking medical assistance once coronary symptoms develop will help to 
reduce the burden of out-of-hospital SCD. 
 
Despite progress in the last few decades in the form of falling CHD incidence and mortality 
rates, MI will likely continue to be a major public health problem both in terms of health and 
economic costs (219). This is due to an ageing population, and increasing prevalence due, in 
part, to decreased mortality, and consequently high numbers of prescriptions for secondary 
prevention. In addition, there is reason to worry about the steady increase in the proportion 
with overweight and diabetes. Measures that can counteract the increase in weight and 
evolution of diabetes will be important in the further preventive work. At the same time, the 
disease panorama is changing: we must expect an increase in the morbidity of degenerative 
heart disease such as heart failure and atrial fibrillation. These conditions show a clear 
relationship with age, and with undergone MI. We must therefore continue to focus on both 













1. U.S. National library of medicine and the National Institutes of Health. Medical subject 
headings. https://meshb.nlm.nih.gov/search 
2. Glossary of epidemiology terms. Columbia University. 
http://www.cs.columbia.edu/digigov/LEXING/CDCEPI/gloss.html 
3. Bhopal R. Concepts of Epidemiology. New York: Oxford University Press, 2002. 
4. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute 
myocardial infarction in patients presenting with ST-segment elevation: the Task Force for 
the management of acute myocardial infarction in patients presenting with ST-segment 
elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-177. 
5. Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to 
precision treatment. Circulation. 2017; 136: 1155–1166.   
6. McManus DD, Gore J, Yarzebski J et al. Recent trends in the incidence, treatment, and 
outccomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47. 
7. Moon JC, De Arenaza DP, Elkington AG et al. The pathologic basis of Q-wave and non-Q-
wave myocardial infarction: a cardiovascular magnetic resonance study. J Am Coll Cardiol. 
2004; 44: 554–560. 
8. Steg PG, James SK, Atar D et al. ESC guidelines for the management of acute myocardial 





9. Roffi  M, Patrono  C, Collet  JP,  et al.  2015 ESC Guidelines for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation: Task 
Force for the Management of Acute Coronary Syndromes in Patients Presenting Without 
Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).  Eur Heart J. 
2016; 37: 267-315. 
10. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial 
revascularization. Eur Heart J 2019; 40: 87-165. 
11. Dudas K, Lappas G, Stewart S et al. Trends in out-of-hospital deaths due to coronary 
heart disease in Sweden (1991 to 2006). Circulation 2011; 123: 46–52. 
12. Chambless L, Keil U, Dobson A et al. Population versus clinical view of case fatality from 
acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Circulation 
1997; 96: 3849–59. 
13. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989; 79: 
756-65. 
14. Monatagnana M, Lippi G, Franchini M et al. Sudden cardiac death: prevalence, 
pathogenesis, and prevention. Ann Med 2008; 40: 360-75.   
15. Zheng ZJ, Croft JB, Giles WH et al. Sudden cardiac death in the United States, 1989 to 
1998. Circulation 2001; 104: 2158-63. 
16. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart 
disease in epidemiology and clinical research studies. Circulation 2003; 108: 2543–9. 




18. Myerburg R, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, 
editor. A Textbook of Cardiovascular Medicine. Philadelphia, PA: Saunders, 1996:742–79. 
19. Kannel WB, Thomas HE Jr. Sudden coronary death: the Framingham Study. Ann N Y Acad 
Sci 1982; 382: 3-21. 
20. Adabag AS, Peterson G, Apple FS et al. Etiology of sudden death in the community: 
results of anatomical, metabolic, and genetic evaluation. Am Heart J. 2010; 159: 33–39. 
21. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Update of the guidelines on sudden 
cardiac death of the European Society of Cardiology. Eur Heart J. 2003; 24: 13-5. 
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major 
outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme 
inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997. 
23. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis 
of randomized controlled trials. JAMA 1999; 282:2340–2346. 
24. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 
366: 321‐9. 
25. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated 
with myocardial infarction in 52 countries (the INTERHEART study): case– control study. 
Lancet 2004; 364: 937–52. 
26. Gregg EW, Cheng YJ, Cadwell BL, et al.  Secular trends in cardiovascular disease risk 




27. Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and pre-diabetes in the U.S. 
population in 1988–1994 and 2005–2006. Diabetes Care. 2009; 32: 287–294. 
28. Women and smoking: a report of the surgeon general. Executive summary. MMRW 
Recomm Rep 2002; 51: 1–30. 
29. Stramba-Badiale M, Fox KM, Priori SG et al. Cardiovascular diseases in women: a 
statement from the policy conference of the European Society of Cardiology. Eur Heart J 
2006; 27: 994–1005. 
30. Anand SS, Islam S, Rosengren A et al. on behalf of the INTERHEART Investigators. Risk 
factors for myocardial infarction in women and men: insights from the INTERHEART study. 
European Heart Journal. 2008; 29: 932–940. 
31. Albrektsen, G., Heuch, I., Lochen, M.L. et al. Lifelong gender gap in risk of incident 
myocardial infarction: the Tromso study. JAMA Intern. Med. 2016; 176: 1673–1679.             
32. Jousilahti P, Vartiainen E, Tuomilehto J et al. Sex, age, cardiovascular risk factors, and 
coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and 
women in Finland. Circulation 1999; 99: 1165–1172. 
33. Roger VL. Epidemiology of myocardial infarction. Med Clin North Am 2007; 91: 537-552. 
34. Nichols M, Townsend N, Scarborough P et al. Cardiovascular disease in Europe 2014: 
epidemiological update. Eur Heart J. 2014; 35: 2950-2959. 
35. Benjamin EJ, Blaha MJ, Chiuve SE et al. American Heart Association Statistics Committee 
and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A 




36. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national 
age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a 
systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171. 
37. Roth GA, Forouzanfar MH, Moran AE et al. Demographic and Epidemiologic Drivers of 
Global Cardiovascular Mortality. N Engl J Med 2015; 372: 1333-1341. 
38. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-
adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) 
for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015; 386: 
2145-91. 
39. Mendis S, Thygesen K, Kuulasmaa K et al and Writing group on behalf of the participating 
experts of the WHO consultation for revision of WHO definition of myocardial infarction. 
World Health Organization definition of myocardial infarction: 2008–09 revision. Int J 
Epidemiol 2011; 40: 139–146. 
40. World Health Organization. Hypertension and coronary heart disease: Classification and 
criteria for epidemiological studies. First report of the expert committee on cardiovascular 
diseases and hypertension. World Health Organization technical report series, No. 168. 
Geneva, 1959. 1959. 
41. Weinstein BJ, Epstein FH; Working Subcommittee on Criteria and Methods, Committee 
on Epidemiological Studies, American Heart Association. Comparability of criteria and 





42. World Health Organization Regional Office for Europe, Working Group on the 
Establishment of Ischaemic Heart Disease Registers. Report of the Fifth Working Group, 
Copenhagen, 26-29 April 1971. Copenhagen, Denmark: Regional Office for Europe, World 
Health Organization; 1971. Report No. Eur 8201(5). 1971 
43. Section 8: Two-year incidence by exam interval by age and sex at exam 1. In: Kannel WB, 
Gordon T, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular 
Disease. Bethesda, Md: US National Heart Institute; 1968. 1968. 
44. Rapaport E. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of 
the Joint International Society and Federation of Cardiology/World Health Organization task 
force on standardization of clinical nomenclature. Circulation 1979; 59: 607–9. 
45. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P et al for WHO MONICA Project. Myocardial 
infarction and coronary deaths in the World Health Organization MONICA Project. 
Registration procedures, event rates and case fatality in 38 populations from 21 countries in 
4 continents. Circulation 1994; 90: 583-612. 
46. Tunstall-Pedoe H, Kuulasmaa K, Mӓhӧnen M et al. Contribution of trends in survival and 
coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 
WHO MONICA project populations. Monitoring trends and determinants in cardiovascular 
disease. Lancet 1999; 353: 1547–1557. 
47. Alpert JS, Thygesen K, Antman E et al. Myocardial infarction redefined--a consensus 
document of The Joint European Society of Cardiology/American College of Cardiology 




48. Richards AM, Lainchbury JG, Nicholls MG. Unsatisfactory redefinition of myocardial 
infarction. Lancet 2001; 357: 1635–6. 
49. Tunstall-Pedoe H. Redefinition of myocardial infarction by a consensus dissenter. J Am 
Coll Cardiol 2001; 37: 1472-4. 
50. French JK, White HD. Clinical implications of the new definition of myocardial infarction. 
Heart 2004; 90: 99–106. 
51. Wong CK, White HD. Myocardial infarction: why can’t we get the diagnosis right? Eur 
Heart J 2003; 24: 1177–9. 
52. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. J Am 
Coll Cardiol 2007; 50: 2173–95. 
53. Thygesen K, Alpert JS, Jaffe AS et al Writing Group on the Joint ESC/ACCF/AHA/WHF Task 
Force for the Universal Definition of Myocardial Infarction, ESC Committee for Practice 
Guidelines. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551–
2567. 
54. Yeh RW, Go AS, MD Rethinking the Epidemiology of Acute Myocardial Infarction 
Challenges and Opportunities. Arch Intern Med. 2010; 170(9): 759-764 
55. Parikh NI, Gona P, Larson MG, et al. Long-term trends in myocardial infarction incidence 
and case fatality in the National Heart, Lung, and Blood Institute’s Framingham Heart Study. 
Circulation. 2009; 119: 1203-1210. 
56. White HD. Evolution of the definition of myocardial infarction: what are the implications 




57. Roger VL, Killian JM, Weston SA, et al. Redefinition of myocardial infarction: prospective 
evaluation in the community. Circulation 2006; 114: 790–7. 
58. Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med 2017; 376: 2053-64. 
59. Roger VL, Weston SA, Gerber Y et al. Trends in incidence, severity, and outcome of 
hospitalized myocardial infarction.  Circulation. 2010; 121: 863–869. 
60. Salomaa V, Ketonen M, Koukkunen H, et al. The effect of correcting for troponins on 
trends in coronary heart disease events in Finland during 1993–2002: the FINAMI study. Eur 
Heart J 2006; 27: 2394–9. 
61. Pell JP, Simpson E, Rodger JC, et al. Impact of changing diagnostic criteria on incidence, 
management, and outcome of acute myocardial infarction: retrospective cohort study. BMJ 
2003; 326: 134–5. 
62. Meier MA, Al-Badr WH, Cooper JV et al. The new definition of myocardial infarction: 
diagnostic and prognostic implications in patients with acute coronary syndromes. Arch 
Intern Med 2002; 162: 1585–1589. 
63. Salomaa V, Koukkunen H, Ketonen M, et al. A new definition for myocardial infarction: 
what difference does it make? Eur Heart J 2005; 26: 1719–1725. 
64. Pell ACH, Pell JP. Was it a heart attack? Variations in access to and interpretation of 
troponin assays are wide [letter]. BMJ 2002; 324: 1216. 
65. Willingham SAM, Kilpatrick ES. Evidence of gender bias when applying the new 




66. Salomaa V, Rosamond W and Mähönen M. Decreasing mortality from acute myocardial 
infarction: effect of incidence and prognosis. J Cardiovasc Risk 1999; 6: 69–75. 
67. Myerson M, Coady S, Taylor H et al, for the ARIC Investigators. Declining severity of 
myocardial infarction 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. 
Circulation 2009; 119: 503–514. 
68. Goldberg RJ. Monitoring trends in severity of acute myocardial infarction: challenges for 
the next millennium. Am Heart J 2000; 139: 767–770. 
69. Giannitsis E, Steen H,  Kurz K et al. Cardiac magnetic resonance imaging study for 
quantification of infarct size comparing directly serial versus single time-point 
measurements of cardiac troponin T, J Am Coll Cardiol 2008; 51: 307-314. 
70. Katus HA, Remppis A, Scheffold TH, et al. Intracellular compartmentation of cardiac 
troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial 
infarction. Am J Cardiol 1991; 67: 1360–7. 
71. Critchley JA, Capewell S. Why model coronary heart disease? Eur Heart J 2002; 23: 110–
116. 
72. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment 
and risk factor changes to the decline in coronary heart disease mortality in Scotland 
between 1975 and 1994. Heart 1999; 81: 380–386. 
73. O’Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining 
CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart. 




74. Laatikainen T, Critchley J, Vartiainen E et al. Explaining the decline in coronary heart 
disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005; 162: 764–773. 
75. Hotchkiss JW, Davies CA, Dundas R et al. Explaining trends in Scottish coronary heart 
disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis 
using routine data. BMJ. 2014; 348: g1088. 
76. Capewell S, Beaglehole R, Seddon M et al. Explanation for the decline in coronary heart 
disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 
102: 1511–1516. 
77. Aspelund T, Gudnason V, Magnusdottir BT, et al. Analyzing the large decline in coronary 
heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 
2006. PLoS ONE 2010;5:e13957. 
78. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary 
disease, 1980-2000. N Engl J Med 2007; 356: 2388–2398. 
79. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease 
mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101–1107. 
80. Bennett K, Kabir Z, Unal B et al. Explaining the recent decrease in coronary heart disease 
mortality rates in Ireland, 1985–2000. J Epidemiol Commun Health 2006; 60: 322–327. 
81. Björck L, Rosengren A, Bennett K et al. Modelling the decreasing coronary heart disease 
mortality in Sweden between 1986 and 2002. Eur Heart J. 2009; 30: 1046-56. 
82. Hu FB, Stampfer MJ, Manson JE et al. Trends in the incidence of coronary heart disease 




83. Hardoon SL, Whincup PH, Lennon LT, et al. How much of the recent decline in the 
incidence of myocardial infarction in British men can be explained by changes in 
cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 
2008; 117: 598-604. 
84. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for 
enhancement and development of evidence-based care in heart disease evaluated according 
to recommended therapies (SWEDEHEART). Heart. 2010; 96: 1617-1621. 
85. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute 
myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
Am Heart J. 2008; 156: 1045-1055. 
86. Fox KA, Steg PG, Eagle KA et al; GRACE Investigators. Decline in rates of death and heart 
failure in acute coronary syndromes, 1999–2006. JAMA. 2007; 297: 1892–1900. 
87. Mehta RH, RoeMT, Chen AY, et al. Recent trends in the care of patients with non-ST–
segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch 
Intern Med. 2006; 166(18): 2027-2034. 
88. Ford ES, Roger VL, Dunlay SM et al. Challenges of ascertaining national trends in the 
incidence of coronary heart disease in the United States. J Am Heart Assoc. 2014; 3(6): 
e001097. 
89. Rosamond WD, Chambless LE, Folsom AR et al Trends in the incidence of myocardial 
infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998; 




90. McGovern PG, Pankow JS, Shahar E et al. Recent trends in acute coronary heart disease: 
mortality, morbidity, medical care, and risk factors. N Engl J Med. 1996; 334: 884–890. 
91. Chen J, Normand SL, Wang Y, et al. Recent declines in hospitalizations for acute 
myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing 
challenges. Circulation 2010; 121: 1322–1328. 
92. Yeh RW, Sidney S, Chandra M et al. Population trends in the incidence and outcomes of 
acute myocardial infarction. N Engl J Med. 2010; 362: 2155–2165. 
93. Rosamond WD, Chambless LE, Heiss G, et al.  Twenty-two-year trends in incidence of 
myocardial infarction, coronary heart disease mortality, and case fatality in 4 US 
communities, 1987-2008.  Circulation. 2012; 125(15): 1848-1857. 
94. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics — 2016 
update: a report from the American Heart Association. Circulation 2016; 133: e38-e360. 
95. Cobb LA, Fahrenbruch CE, Olsufka M et al. Changing incidence of out-of-hospital 
ventricular fibrillation, 1980–2000. JAMA. 2002; 288: 3008–3013. 
96. McManus DD, Piacentine SM, Lessard D, et al. Thirty-year (1975 to 2005) trends in the 
incidence rates, clinical features, treatment practices, and short-term outcomes of patients 
<55 years of age hospitalized with an initial acute myocardial infarction. Am J Cardiol 2011; 
108: 477-82. 
97. Sulo G, Igland J, Nygard O et al. Favourable trends in incidence of AMI in Norway during 





98. Yang D, Dzayee DA, Beiki O, et al. Incidence and case fatality after day 28 of first time 
myocardial infarction in Sweden 1987–2008. Eur J Prev Cardiol 2012; 19: 1304–1315. 
99. Pajunen P, Paakkonen R, Juolevi A, et al. Trends in fatal and non-fatal coronary heart 
disease events in Finland during 1991–2001. Scand Cardiovasc J 2004; 38: 340–344. 
100. Fischer T, Lundbye-Christensen S, Johnsen SP, et al. Secular trends and seasonality in 
first-time hospitalization for acute myocardial infarction – a Danish population-based study. 
Int J Cardiol 2004; 97: 425–431. 
101. Schmidt M, Jacobsen JB, Lash TL et al. 25 year trends in first time hospitalization for 
acute myocardial infarction, subsequent short and long term mortality, and the prognostic 
impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012; 344: e356. 
102. Koopman C, Bots ML, van Oeffelen AA, et al. Population trends and inequalities in 
incidence and short-term outcome of acute myocardial infarction between 1998 and 2007. 
Int J Cardiol 2013; 168: 993-8. 
103. Davies AR, Grundy E, Nitsch D et al. Constituent country inequalities in myocardial 
infarction incidence and case fatality in men and women in the United Kingdom, 1996-2005. 
J Public Health (Oxf) 2011; 33: 131-8. 
104. Dudas K, Lappas G, Rosengren A. Long-term prognosis after hospital admission for acute 
myocardial infarction from 1987 to 2006. Int J Cardiol. 2012; 155: 400-5. 
105. Fornari C, Cesana GC, Chambless LE, et al. Time trends of myocardial infarction 28-day 
case-fatality in the 1990s: is there a contribution from different changes among 




106. Langorgen J, Igland J, Vollset SE et al. Short-term and long-term case fatality in 11 878 
patients hospitalized with a first acute myocardial infarction, 1979-2001: the Western 
Norway cardiovascular registry. Eur J Cardiovasc Prev Rehabil 2009; 16: 621–7. 
107. Oyen N, Nygard O, Igland J, et al. Hospital admission rates for cardiovascular diseases in 
Western Norway, 1992–2001. Tidsskr Nor Laegeforen 2008; 128: 17–23. 
108. Roger VL, Weston SA, Killian JM, et al. Time trends in the prevalence of atherosclerosis: 
a population-based autopsy study. Am J Med 2001; 110: 267-73. 
109. Webber BJ, Seguin PG, Burnett DG, et al. Prevalence of and risk factors for autopsy-
determined atherosclerosis among US service members, 2001-2011. JAMA 2012;308:2577-
83. 
110. Jennings SM, Bennett K, Lonergan M et al. Trends in hospitalisation for acute 
myocardial infarction in Ireland, 1997-2008. Heart 2012; 98: 1285-1289. 
111. Maier B, Thimme W, Schoeller R et al. Improved therapy and outcome for patients with 
acute myocardial infarction – Data from the Berlin myocardial infarction register from 1999 
to 2004. Int J Cardiol 2008; 130: 211-219. 
112. Khera S, Kolte D, Gupta T et al. Temporal trends and sex differences in revascularization 
and outcomes of st-segment elevation myocardial infarction in younger adults in the United 
States. J Am Coll Cardiol 2015; 66: 1961–1972. 
113. Terkelsen CJ, Lassen JF, Norgaard BL et al. Mortality rates in patients with ST-elevation 
vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. 




114. Towfighi A, Markovic D, Ovbiagele B. National gender-specific trends in myocardial 
infarction hospitalization rates among patients aged 35 to 64 years. Am J Cardiol 2011; 108: 
1102-7. 
115. Roger VL, Jacobsen SJ, Weston SA et al. Trends in the incidence and survival of patients 
with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann 
Intern Med 2002; 136: 341–348. 
116. Lehto HR, Lehto S, Havulinna AS, et al. Are coronary event rates declining slower in 
women than in men — evidence from two population-based myocardial infarction registers 
in Finland? BMC Cardiovasc Disord 2007; 7: 35. 
117. Lundblad D, Holmgren L, Jansson JH et al. Gender differences in trends of acute 
myocardial infarction events: the Northern Sweden MONICA study 1985–2004. BMC 
Cardiovasc Disord 2008; 8: 17. 
118. Nedkoff LJ, Briffa TG, Preen DB, et al. Age- and sex-specific trends in the incidence of 
hospitalized acute coronary syndromes in Western Australia. Circ Cardiovasc Qual Outcomes 
2011; 4: 557–564. 
119. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease 
risk and prevalence. Arch Intern Med 2009; 169: 1762-6. 
120. Egred M, Viswanathan G, Davis GK. Myocardial infarction in young adults. Postgrad Med 
J 2005; 81: 741–745. 
121. Widimsky P, Wijns W, Fajadet J, et al; European Association for Percutaneous 




infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2010; 
31(8): 943-957. 
122. The Reperfusion Therapy Consensus Group. Selection of reperfusion therapy for 
individual patients with evolving myocardial infarction. Eur Heart J 1997; 18: 1371–81. 
123. Keeley EC, Boura JA, Grines C. Primary angioplasty versus intravenous thrombolytic 
therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. 
Lancet 2003; 361: 13–20. 
124. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-
hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur 
Heart J. 2009; 30: 1598-606. 
125. Morrison LJ, Verbeek PR, McDonald AC et al. Mortality and pre-hospital thrombolysis 
for acute myocardial infarction: A meta-analysis. JAMA 2000; 283: 2686–2692. 
126. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital 
fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002; 360: 825-9. 
127. Danchin N, Puymirat E, Steg PG, et al. Five-year survival in patients with ST-segment-
elevation myocardial infarction according to modalities of reperfusion therapy: the French 
Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 
Cohort. Circulation. 2014; 129: 1629-36. 
128. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-
segment elevation myocardial infarction. N Engl J Med. 2013; 368: 1379-87. 
129. Boersma E, Maas ACP, Deckers JW et al. Early thrombolytic treatment in acute 




130. Steg PG, Bonnefoy E, Chabaud S et al. Impact of time to treatment on mortality after 
pre-hospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical 
trial. Circulation 2003; 108: 2851–2856. 
131. Pinto DS, Frederick PD, Chakrabarti AK et al. Benefit of transferring ST-segment-
elevation myocardial infarction patients for percutaneous coronary intervention compared 
with administration of onsite fibrinolytic declines as delays increase. Circulation 2011; 124: 
2512–2521. 
132. Westerhout CM, Bonnefoy E, Welsh RC et al. The influence of time from symptom onset 
and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled 
analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention 
from CAPTIM and WEST. Am Heart J. 2011; 161(2): 283-90. 
133. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 
hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial 
infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 
2004; 364: 1045-53. 
134. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed 
thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005; 353: 2758-68. 
135. Borgia F, Goodman SG, Halvorsen S et al. Early routine percutaneous coronary 
intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial 




136. D’Souza SP, Mamas MA, Fraser DG et al. Routine early coronary angioplasty versus 
ischaemia-guided angioplasty after thrombolysis in acute STelevation myocardial infarction: 
a meta-analysis. Eur Heart J 2011; 32: 972–982. 
137. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised 
trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of 
suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360. 
138. Sabatine MS, Cannon CP, Gibson CM et al, CLARITY-TIMI 28 Investigators. Addition of 
clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment 
elevation. N Engl J Med 2005; 352(12): 1179–1189. 
139. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 
Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, 
or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
Lancet 2001; 358: 605–613. 
140. Jernberg T, Johanson P, Held C et al; SWEDEHEART/RIKS-HIA. Association between 
adoption of evidence-based treatment and survival for patients with ST-elevation myocardial 
infarction. JAMA. 2011; 305: 1677-84. 
141. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic 
therapy in suspected acute myocardial infarction: collaborative overview of early mortality 
and major morbidity results from all randomised trials of more than 1000 patients. Lancet 




142. Ng VG, Lansky AJ, Meller S et al. The prognostic importance of left ventricular function 
in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Eur 
Heart J Acute Cardiovasc Care 2014; 3: 67–77. 
143. Sutton NR, Li S, Thomas L et al. The association of left ventricular ejection fraction with 
clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment 
and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) 
Medicare-linked database. Am Heart J 2016; 178: 65–73. 
144. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive 
an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% 
should receive an implantable cardioverter-defibrillator. Circulation. 2005; 111: 2537–2549. 
145. The Multicenter Postinfarction Research Group. Risk stratification and survival after 
myocardial infarction. N Engl J Med. 1983; 309: 331–336. 
146. Rouleau JL, Talajic M, Sussex B et al. Myocardial infarction patients in the 1990s—their 
risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial 
Infarction (CAMI) Study. J Am Coll Cardiol. 1996; 27: 1119 –1127. 
147. Velagaleti RS, Pencina MJ, Murabito JM et al. Long-term trends in the incidence of heart 
failure after myocardial infarction. Circulation 2008; 118: 2057–2062. 
148. Desta L, Jernberg T, Lofman I et al. Incidence, temporal trends, and prognostic impact of 
heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish 
Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease 
Evaluated According to Recommended Therapies): a study of 199,851 patients admitted 




149. Goldberg RJ, Spencer FA, Gore JM et al. Thirty-year trends (1975 to 2005) in the 
magnitude of, management of, and hospital death rates associated with cardiogenic shock in 
patients with acute myocardial infarction a population-based perspective. Circulation 2009; 
119: 1211–1219. 
150. Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: 
epidemiological update 2016. Eur Heart J 2016; 37(42): 3232–3245. 
151. Puymirat E, Simon T, Steg PG et al, USIK USIC 2000 Investigators, FAST MI Investigators. 
Association of changes in clinical characteristics and management with improvement in 
survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308(10): 998–
1006. 
152. Gale CP, Allan V, Cattle BA et al. Trends in hospital treatments, including 
revascularisation, following acute myocardial infarction, 2003-2010: a multilevel and relative 
survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR). 
Heart 2014; 100(7): 582–589. 
153. Pedersen F, Butrymovich V, Kelbaek H et al. Short- and long-term cause of death in 
patients treated with primary PCI for STEMI. J Am Coll Cardiol 2014; 64: 2101–2108. 
154. Fokkema ML, James SK, Albertsson P et al. Population trends in percutaneous coronary 
intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and 
Angioplasty Registry). J Am Coll Cardiol 2013; 61: 1222–1230. 
155. Mandelzweig L, Battler A, Boyko V et al. The Second Euro Heart Survey on Acute 
Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in 




156. Jacobsen BK, Eggen AE, Mathiesen EB et al. Cohort profile: the Tromso Study. Int J 
Epidemiol. 2012; 41: 961-967. 
157. Njølstad I, Mathiesen EB, Schirmer H et al. The Tromsø study 1974–2016: 40 years of 
cardiovascular research. Scandinavian Cardiovascular Journal 2016; 50: 276-281. 
158. WHO MONICA Project. MONICA Manual. https://thl.fi/publications/monica/index.html 
http://www.thl.fi/publications/morgam/manual/contents.htm Accessed 06 January, 2019 
159. Eggen AE, Mathiesen EB, Wilsgaard T et al. The sixth survey of the Tromso Study 
(Tromso 6) in 2007-08: collaborative research in the interface between clinical medicine and 
epidemiology: study objectives, design, data collection procedures, and attendance in a 
multipurpose population-based health survey. Scand J Public Health. 2013; 41: 65–80. 
160. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular 
clinical trials: a consensus report from the Bleeding Academic Research Consortium. 
Circulation. 2011; 123: 2736-47. 
161. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995; 51: 
524–532. 
162. Jortveit J, Govatsmark RE, Digre TA, et al. Myocardial infarction in Norway in 2013. 
Tidsskr Nor Laegeforen. 2014; 134: 1841-6. 
163. Grimes DA, Schulz KF. Descriptive studies: what they can and cannot do. Lancet.  2002; 
359: 145-9. 






165. NCI Dictionary of Cancer Terms. 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/nonconsecutive-case-
series?redirect=true 
166. Chan K, Bhandari M. Three-minute critical appraisal of a case series article. Indian J 
Orthop 2011; 45: 103-104. 
167. Mathes T, Pieper D. Clarifying the distinction between case series and cohort studies in 
systematic reviews of comparative studies: potential impact on body of evidence and 
workload. BMJ Medical Research Methodology 2017; 17: 107. 
168. Kooistra B, Dijkman B, Einhorn TA et al. How to design a good case series. J Bone Joint 
Surg Am. 2009; 91 Suppl 3: 21-6. 
169. Armstrong BK, White E, Saracci R. Principles of exposure measurement in epidemiology.  
New York: Oxford University Press, 1992. 
170. Schwarz, PE, Muylle F, Valensi P, et al. The European perspective of diabetes 
prevention. Horm Metab Res 2008; 40: 511-514. 
171. Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber 
quantification by echocardiography in adults: an update from the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J 
Cardiovasc Imaging 2015; 16: 233-271. 
172. Quinones MA, Douglas PS, Foster E et al. ACC/AHA clinical competence statement on 
echocardiography: a report of the American College of Cardiology/American Heart 
Association/American College of Physicians–American Society of Internal Medicine Task 




173. Kleijn SA, Aly MFA, Terwee CB: Reliability of left ventricular volumes and function 
measurements using three‐dimensional speckle tracking echocardiography. Eur Heart J 
Cardiovasc Imaging 2012; 13: 159–168. 
174. Hoffmann R, von Bardeleben S, Kasprzak JD et al. Analysis of regional left ventricular 
function by cineventriculography, cardiac magnetic resonance imaging, and unenhanced and 
contrast-enhanced echocardiography: a multicenter comparison of methods. J Am Coll 
Cardiol 2006; 47: 121–8. 
175. Blondheim DS, Beeri R, Feinberg MS et al. Reliability of visual assessment of segmental 
and global left ventricular function: a multicenter study by the Israeli Echocardiography 
Research Group. J Am Soc Echocardiogr 2010; 23: 258–64. 
176. Kaufmann BA, Min SY, Goetschalckx K et al. How reliable are left ventricular ejection 
fraction cut offs assessed by echocardiography for clinical decision making in patients with 
heart failure? Int J Cardiovasc Imaging 2013; 29: 581–588. 
177. Greenland S, Robins JM, Pearl J. "Confounding and Collapsibility in Causal Inference". 
Statistical Science 1999; 14: 29–46. 
178. Mamdani M, Sykora K, Li P, et al.  Reader's guide to critical appraisal of cohort studies, 
2: Assessing potential for confounding.  BMJ. 2005; 330: 960-962. 
179. Zaccai JH. How to assess epidemiological studies. Postgrad Med J 2004; 80: 140-147. 





181. Nemetz PN, Roger VL, Ransom JE et al. Recent trends in the prevalence of coronary 
disease. A population-based autopsy study of nonnatural deaths. Arch Intern Med 2008; 
168: 264–270. 
182. Evans A, Tolonen H, Hense H-W et al for the WHO MONICA Project. Trends in coronary 
risk factors in the WHO MONICA Project. International journal of epidemiology 2001; 30: 
S35-S40. 
183. Molarius A, Parsons RW, Dobson AJ et al: Trends in cigarette smoking in 36 populations 
from the early 1980s to the mid-1990s: findings from the WHO MONICA Project. Am J Public 
Health 2001; 91(2): 206-212. 
184. Grundtvig M, Hagen TP, German M et al. Sex-based differences in premature first 
myocardial infarction caused by smoking: twice as many years lost by women as by men. Eur 
J Cardiovasc Prev Rehabil 2009; 16: 174–179. 
185. Norgeshelsa.  http://norgeshelsa.no/norgeshelsa/?language=en (accessed March 2018). 
186. The Tromsø Study. http://tromsoundersokelsen.uit.no/tromso/ (accessed March 2018). 
187. Tunstall-Pedoe H, Woodward M, Tavendale R et al: Comparison of the prediction by 27 
different factors of coronary heart disease and death in men and women of the Scottish 
Heart Health Study: cohort study. BMJ (Clinical research ed) 1997; 315(7110): 722-729. 
188. Prescott E, Hippe M, Schnor P et al. Smoking and risk of myocardial infarction in women 
and men: longitudinal population study. BMJ 1998; 316: 1043–1047. 
189. Lee WL, Cheung AM, Cape D et al. Impact of diabetes on coronary artery disease in 




190. Mosca L, Appel LJ, Benjamin EJ et al: Evidence-based guidelines for cardiovascular 
disease prevention in women. Circulation 2004, 109(5):672-693. 
191. Brieger D, Eagle KA, Goodman SG et al. Acute coronary syndromes without chest pain, 
an underdiagnosed and undertreated high-risk group: insights from the Global Registry of 
Acute Coronary Events. Chest 2004; 126: 461–469. 
192. Mosca L, Ferris A, Fabunmi R et al. Tracking women’s awareness of heart disease. An 
American Heart Assosiation National Study. Circulation 2004; 109: 573–579. 
193. Mosca L, Mochari-Greenberger H, Dolor RJ et al. Twelve-year follow-up of American 
women’s awareness of cardiovascular disease risk and barriers to heart health. Circ 
Cardiovasc Qual Outcomes. 2010; 3: 120–127. 
194. Hochman JS, McCabe CH, Stone PH et al. Outcome and profile of women and men 
presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. 
Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1997; 30: 141-8. 
195. Rosengren A, Wallentin L, Gitt AK et al: Sex, age, and clinical presentation of acute 
coronary syndromes. Eur Heart J 2004, 25(8): 663-670. 
196. Mahon NG, McKenna CJ, Codd MG et al. Gender differences in the management and 
outcome of acute myocardial infarction in unselected patients in the thrombolytic era. Am J 
Cardiol 2000; 85(8): 921–926. 
197. Burke AP, Farb A, Malcom GT et al. Coronary risk factors and plaque morphology in men 
with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282. 
198. Albert CM, Ruskin JN. Risk stratifiers for sudden cardiac death (SCD) in the community: 




199. Johansen CD, Olsen RH, Pedersen LR et al. Resting, night-time, and 24 h heart rate as 
markers of cardiovascular risk in middle-aged and elderly men and women with no apparent 
heart disease. Eur Heart J. 2013; 34: 1732–1739.  
200. Jouven X, Empana JP, Schwartz PJ et al. Heart-rate profile during exercise as a predictor 
of sudden death. N Engl J Med. 2005; 352: 1951–1958.  
201. Fox K, Borer JS, Camm AJ et al; Heart Rate Working Group. Resting heart rate in 
cardiovascular disease. J Am Coll Cardiol. 2007; 50: 823–830.   
202. Rosengren A, Wallentin L,  Simoons M et al. Cardiovascular risk factors and clinical 
presentation in acute coronary syndromes, Heart , 2005; 91: 1141-1147. 
203. Levantesi G, Scarano M, Marfisi R, et al: Metaanalysis of effect of statin treatment on 
risk of sudden death. Am J Cardiol 2007; 100: 1644-1650. 
204. Spencer FA, Santopinto JJ, Gore JM et al. Impact of aspirin on presentation and hospital 
outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary 
Events [GRACE]). Am J Cardiol. 2002; 90: 1056-61. 
205. Go AS, Iribarren C, Chandra M, et al. Statin and beta-blocker therapy and the initial 
presentation of coronary heart disease. Ann Intern Med 2006; 144: 229-38. 
206. Capewell S, O’Flaherty M. Can dietary changes rapidly decrease cardiovascular mortality 
rates? Eur Heart J 2011; 32: 1187-9. 
207. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public 




208. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing 
polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of 
randomized controlled trials. PLoS Med 2010; 7: e1000252. 
209. Ström A, Jensen RA. Mortality from circulatory diseases in Norway 1940–1945. Lancet 
1951; 1: 126–29. 
210. Salomaa V, Ketonen M, Koukkunen H et al. Decline in out-of hospital coronary heart 
disease deaths has contributed the main part to the overall decline in coronary heart disease 
mortality rates among persons 35 to 64 years of age in Finland: the FINAMI study. 
Circulation. 2003; 108: 691–696. 
211. Engdahl J, Holmberg M, Karlson BW et al. The epidemiology of out-of-hospital “sudden” 
cardiac arrest. Resuscitation. 2002; 52: 235–245. 
212. Saczynski JS, Yarzebski J, Lessard D et al. Trends in prehospital delay in patients with 
acute myocardial infarction (from the Worcester Heart Attack Study). Am J Cardiol. 2008; 
102: 1589–1594. 
213. Gerber Y, Weston SA, Jiang R et al. The changing epidemiology of myocardial infarction 
in Olmsted County, Minnesota, 1995-2012. Am J Med. 2015; 128: 144–151. 
214. Sulo E, Vollset SE, Nygard O. Trends in 28-day and 1-year mortality rates in patients 
hospitalized for a first acute myocardial infarction in Norway during 2001–2009: a 
“Cardiovascular disease in Norway” (CVDNOR) project. J Intern Med 2015; 277(3): 353–361. 
215. Fothergill RT, Watson LR, Virdi GK et al. Survival of resuscitated cardiac arrest patients 
with ST-elevation myocardial infarction (STEMI) conveyed directly to a Heart Attack Centre 




216. Terkelsen CJ, Sorensen JT, Maeng M et al. System delay and mortality among patients 
with STEMI treated with primary percutaneous coronary intervention. JAMA 2010; 304: 763–
771. 
217. Roule V, Ardouin P, Blanchart K, et al. Prehospital fibrinolysis versus primary 
percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic 
review and meta-analysis of randomized controlled trials. Crit Care. 2016; 20(1): 359. 
218. Bohmer E, Hoffmann P, Abdelnoor M et al. Efficacy and safety of immediate angioplasty 
versus ischemia-guided management after thrombolysis in acute myocardial infarction in 
areas with very long transfer distances results of the NORDISTEMI (NORwegian study on 
DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010; 55: 102-10. 
219. Bhatnagar P, Wickramasinghe K, Williams J et al. The epidemiology of cardiovascular 
disease in the UK 2014. Heart 2015; 0: 1-8. 
